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ABSTRACT
This work describes the structure of human 5-lipoxygenase (5-LOX) (Gilbert, Bartlett et
al. 2011) and the techniques required to ascertain the structure. 5-LOX is a notoriously unstable
enzyme with important biological functions. The human 5-LOX has been implicated in many
disease states including asthma, atherosclerosis and cancer. Part of 5-LOX biology is the
inherent instability of the enzyme, which is thought to help regulate the production of its proinflammatory products, the leukotrienes. Our objective was stabilizing the enzyme for in vitro
studies without affecting catalytic fidelity. I was able to quantitate stabilizing and destabilizing
point mutations of 5-LOX by thermal denaturation and kinetic analysis along with other
biochemical techniques. Through rigorous site-directed mutagenesis experiments and multiple
expression protocols, I was able to over-express an engineered form of 5-LOX that is soluble
and stable for biochemical studies and most importantly amenable to crystallization. Our lab is
the first to crystallize a human lipoxygenase and model the molecular details.
Another objective was studying the effect of phosphorylation on specific serine residues
in 5-LOX that have been previously shown to be phosphorylated in vitro. I focused on
phosphorylation of Ser663, which is ten amino acids removed from the C-terminus that
penetrates the 5-LOX body and binds to the catalytic iron. I mutated this Ser663 to an aspartate,
which is a mutation that has been previously shown to mimic a phosphorylated serine. The
mutant 5-LOX S663D has altered product specificity in that it oxygenates arachidonic acid (AA)
on the 15 carbon preferentially instead of the 5 carbon. This dual specificity of 5-LOX could alter
the amounts of the pro- and/or anti-inflammatory compounds present at sites of activation.
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With the structure of human 5-LOX solved and with reproducible crystal conditions, I
began co-crystallization trials of 5-LOX with AA but devoid of oxygen, the other substrate. This
would allow visualization of the important substrate binding amino acids and the catalytic
machinery necessary for leukotriene production. I was able to model the placement of AA into
the active site of Stable-5-LOX S663D, and this structure revealed striking conformational
changes required for substrate binding. With these structural studies along with future cocrystallization studies with inhibitors, I will be able to describe amino acids important for
catalysis. These insights afforded from co-crystal structures could aid in the development of
therapies for the treatment of certain diseases caused by 5-LOX.

x

CHAPTER ONE
REVIEW OF LITERATURE
Overview
The leukotrienes have been studied for over 30 years and much has been learned about
the biosynthesis of these inflammatory products. The word leukotriene is composed of “leuko”
specifying that the products are found primarily in leukocytes, and “triene” designating that
there are three double bonds, which provide a spectrophotometric signal for detection of this
product. The leukotriene pathway is initiated with synthesis of leukotriene A4 (LTA4) in a twostep reaction by the action of 5-lipoxygenase (5-LOX). Arachidonic acid (AA) is the preferred
substrate and is a component of the membrane phospholipids until liberation by cytosolic
phospholipase A2 (cPLA2). The first committed step of leukotriene biosynthesis is the conversion
of AA to the 5(S) isomer of 5-hydroperoxyeicosatetraenoic acid (5-HpETE). 5-LOX has a helper
protein 5-lipoxygenase-activating protein (FLAP), which is thought to sequester substrate, and
in vivo studies have shown that there is little leukotriene production without the help of FLAP.
FLAP also increases the ratio of LTA4 to 5-HpETE production. The different fates of the highly
unstable LTA4 depend on subcellular location, transcellular biosynthetic machinery and cell
type. Modification of LTA4 by leukotriene C4 synthase (LTC4 synthase) produces the class of
cysteinyl leukotrienes, which were first coined the “slow-reacting substance of anaphylaxis”
(SRS-A). The cysteinyl leukotrienes C4 (LTC4), D4 (LTD4) and E4 (LTE4) elicit their biological
response by binding to the specific G-protein coupled receptors CysLT1 and CysLT2. This results
in a smooth muscle contraction in lung epithelia and vascular permeability of cells into the
1

surrounding tissues. The other enzymatic avenue of LTA4 is the production of leukotriene B4
(LTB4) by leukotriene A4 hydrolase (LTA4 hydrolase). LTB4 binds to the GPCR BLT1 and/or BLT2
and promotes the recruitment of leukocytes to a particular site of inflammation by chemotactic
and chemokinetic agents.
The enzymes of leukotriene biosynthesis and response are druggable human targets for
inhibition studies, and currently there are two classes of drugs on the market that bind to either
5-LOX or CysLT1. Druggable describes the potential of a protein to be modulated by a small
molecule. Both the cysteinyl leukotrienes and LTB4 are pro-inflammatory molecules that have
been implicated in asthma, in the initiation of atherosclerosis, and in the progression of certain
cancers. Solving the structure of the enzyme that initiates the synthesis of leukotrienes will help
advance the knowledge of the early events of leukotriene biosynthesis and could aid in the
production of new potent inhibitors of 5-LOX.

Discovery of Leukotrienes
An effector classified as slow reacting substance (SRS) that is responsible for triggering
the contraction of smooth muscle was first discovered in 1938 in guinea pig lung epithelium
that was treated with cobra venom (Feldberg and Kellaway 1938). In 1940, this SRS was found
to be an important mediator of asthma and other hypersensitivity reactions. When the SRS is
immunologically generated, the SRS is referred to as a “slow reacting substance of anaphylaxis”
(SRS-A). The molecular composition of SRS-A took over 40 years to complete, and it is now
known to consist of the class of leukotrienes that are conjugated to glutathione (GSH) by LTC4
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synthase. These GSH conjugated or cysteinyl leukotrienes consist of leukotriene C4, leukotriene
D4 and leukotriene E4 (Hammarstrom, Murphy et al. 1979; Samuelsson, Borgeat et al. 1979;
Samuelsson 1983). The 5-LOX enzyme that begins the synthesis of the SRS-A was first
discovered in 1976 by incubating rabbit polymorphonuclear leukocytes with arachidonic acid. 5LOX inserts a molecular oxygen on C-5 of arachidonic acid to form 5S-hydroperoxy-6,8,11,14-

Figure 1. Early Leukotriene Pathway. The substrate arachidonic acid is first dioxygenated by
the enzyme 5-LOX on C-5 to form 5-hydroperoxyeicostetraenoic acid and is further modified by
reaction on carbon 10 to form the allylic epoxide LTA4. There are two main enzymatic fates of
LTA4: hydrolysis by LTA4 hydrolase to form LTB4 or conjugation with glutathione (GSH) by LTC4
synthase to make LTC4 (Murphy and Gijon 2007). Glutathione is a tripeptide of γ-glutamylcysteinyl glycine that acts as strong reducing agent in cells. LTC4 is exported out of the cell
where it can be processed by γ-glutamyl transpeptidase to LTD4 and subsequently to LTE4 by
dipeptidase hydrolysis.
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eicosatetraenoic acid (5-HpETE) and was shown later to react with 5-HpETE at C-10 to produce
the unstable epoxide LTA4 (Borgeat, Hamberg et al. 1976; Borgeat and Samuelsson 1979). An
alternate fate of LTA4 was later described as being enzymatically hydrolyzed to form the
dihydroxyl leukotriene B4 by LTA4 hydrolase (Fig 1) (Borgeat and Samuelsson 1979; Borgeat and
Samuelsson 1979).

Early Steps in Leukotriene Biosynthesis
Leukotriene biosynthesis begins with cell activation, most notably by calcium release
into the cytosol. Both 5-LOX and cytosolic phospholipase A2 (cPLA2) bind calcium and are
targeted to the nuclear membrane. Other stimuli that activate both cPLA2 and 5-LOX and
induce LT formation in whole cell assays include formyl-methionyl-leucyl-phenylalanine (fMLP),
calcium ionophore A23187 or thapsigargin, opsonized zymosan, platelet-activating factor (PAF),
phorbol myristate acetate (PMA) and specific cytokines (Radmark and Samuelsson 2005).
Thapsigargin and calcium ionophore A23187 increase cytosolic Ca2+ concentrations by inhibiting
sarco/ endoplasmic reticulum Ca2+ ATPase from pumping calcium out of the cytosol into the
sarcoplasm or ER and chelating Ca2+ for intracellular import, respectively (Rogers, Inesi et al.
1995). PAF and fMLP bind to specific GPCRs on the outside of the cell where pro-inflammatory
events are activated inside the cell through calcium release and activation of other secondary
messengers (Prescott, Zimmerman et al. 2000). fMLPs are degradation products of bacteria and
mitochondria and are strong chemoattractants for macrophages and other leukocytes (Nguyen
and Pei 2005). Zymosan is a glucan that induces the production of pro-inflammatory cytokines,
which subsequently mobilizes arachidonic acid and induces protein phosphorylation events
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(Miyasato, Taguchi et al. 1994). Opsonization of zymosan enhances the binding of phagocytizing
cell receptors to the inflammation inducer and primes other macrophages in the area. PMA is a
potent tumor promoter, which like zymosan, activates protein-phosphorylation signal
transduction events inside the cell that upregulate the synthesis of pro-inflammatory
compounds (Castagna, Takai et al. 1982). Most of these soluble agonists listed above, along
with others not discussed here, stimulate a less pronounced Ca2+ influx (Werz 2002) and reflect
a more biologically relevant amount of Ca2+ activation of 5-LOX compared to ionophore
induction (Clancy, Dahinden et al. 1983; Wong, Cook et al. 1991). 5-LOX and cPLA2 are activated
similarly in two ways, by calcium upregulation and phosphorylation events (Pouliot, McDonald
et al. 1996; Werz, Klemm et al. 2000). These activation events relocate the enzymes to specific
subcellular compartments for catalysis, and sequestering multiple enzymes of the same
biosynthetic pathway in a similar location could be beneficial for increasing product formation.

Calcium Activation
5-LOX is stimulated by many cofactors that help regulate the synthesis of the LTs.
Calcium was one of the first described activators of leukotriene production, and it stimulates
both the dioxygenase and hydrolase reaction of 5-LOX. Upon addition of the ionophore A23187,
Ca2+ levels are increased inside the cell by A23187 mediated transport of Ca2+ across the cell
membrane. This Ca2+-stimulation of leukotriene biosynthesis was first described in RBL-1 cell
homogenates with increased production of 5-HETE (Jakschik, Sun et al. 1980). Half-maximal
activity of 5-HpETE production is reached upon addition of 1-2 µM Ca2+ , and full activation has
been reported at concentrations of 4-10 µM Ca2+ (Percival, Denis et al. 1992; Noguchi, Miyano
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et al. 1994). The Kd for calcium binding to 5-LOX was reported as 6 µM (Hammarberg and
Radmark 1999). The number of Ca2+ ions bound per protein is considered to be two or three
ions (Kulkarni, Das et al. 2002; Newcomer and Gilbert 2010). Equilibrium dialysis experiments
on 5-LOX revealed a reversible binding average of two Ca2+ ions, and further experiments with
only the His-tagged C2-like domain supported the evidence of two Ca2+ ions per monomer
(Kulkarni, Das et al. 2002). There may be a high affinity calcium binding site unrevealed by the
previous experiments. Sequence conservation data, along with structures of close homologues
of the Ca2+ binding domain of 5-LOX, suggest there could indeed be a third Ca2+ bound to the
C2-like domain of 5-LOX (FIG 2). The sequence of Plexaura homomalla 8R-lipoxygenase (8RLOX) and Clostridium perfringens gangrene α-toxin phospholipase C (α-toxin PLC) have strict
conservation of Ca2+ binding amino acids with 5-LOX , and both x-ray crystal structures of

Figure 2. Sequence alignment of C2-like domains. The sequences of the C2-like domains of 8RLOX, 5-LOX and α-toxin PLC were aligned using ClustalW2. The red boxes detail amino acids
utilized in Ca2+ binding in 8R-LOX and α-toxin PLC and that are conserved in 5-LOX. Green boxes
enclose amino acids that reside in superficial loops thought to insert into the lipid bilayer. Trp75
of 5-LOX is thought to penetrate ~9 Å deep into the bilayer. 5-LOX conservation with α-toxin
PLC and 8R-LOX supports that three Ca2+ ions bind per C2-like domain of 5-LOX (Oldham, Brash
et al. 2005).
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8R-LOX and α-toxin PLC revealed three Ca2+ ions bound per β-barrel domain (Fig 3) (Oldham,
Brash et al. 2005).

Figure 3. Structural comparisoin of C2-like domains. (Left) Cartoon representation of the C2like domain of 8R-LOX (Protein Data Bank accession code, 2FNQ) is shown in grey. Ca2+ ions are
shown as yellow spheres, and amino acids required for Ca2+ binding or membrane insertion are
illustrated as grey or blue sticks, respectively. (Right) Superimposition of 8R-LOX (red, 2FNQ), αtoxin PLC (blue, Protein Data Bank accession code,1QMD) are illustrated in cartoon rendering.
Ca2+ ions from 8R-LOX and α-toxin PLC are shown as red or blue spheres, respectively and bind
to the loop region of the C2 domain. Sequence identity suggests that 5-LOX shares all three
calcium binding motifs with 8R-LOX and α-toxin PLC (Oldham, Brash et al. 2005).
Calcium is predicted to bind to the C2-like domain, also known as the Polycystin-1,
Lipoxygenase, and α-Toxin (PLAT) domain, of 5-LOX (Allard and Brock 2005). The C2 domain was
first identified in protein kinase C (PKC). PKC has a Ca2+-dependent C2 domain, but not all C2
domains are regulated by calcium, and they may play other structural roles (Nalefski and Falke
1996). C2 domains have been found in many intracellular-regulatory proteins and play a diverse
role in the control of protein phosphorylation, production of lipid-secondary messages,
membrane trafficking, activation of certain GTPases, and in ubiquitin ligation (Nalefski, Wisner
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et al. 2001). The C2 domain is a β-sandwich of two four-stranded β-strands. The loops that
connect the β-sandwich are poorly conserved across the C2 domain family. The loop regions are
where Ca2+ binds and aspartate side-chains are the main determinants for Ca2+ binding with
other main chain carbonyls also filling the coordination sphere. There are two basic topological
folds of the C2 domain: type I (synaptotagmin I) with N- and C-termini on the same side of the
β-barrel and type II (phosphoinositide-specific phospholipase C-δ1) with N- and C-termini on
opposite sides.
The N-terminal C2-like domain of 5-LOX is highly negatively charged, and Ca2+ binding
could help neutralize this charge or interact with the negative charge of the phosphate in the
phosphatidyl membrane (Kulkarni, Das et al. 2002). The Ca2+ binding also appears to affect the
hydrophobicity of the C2-like domain of 5-LOX by exposing tryptophans 13 and 75. Trp75 of 5LOX has been reported to insert ~9 Å deep into the bilayer (Pande, Qin et al. 2005). 5-LOX has
also been shown to preferentially bind to positively charged phospholipids with
polyunsaturated fatty acids (Pande, Moe et al. 2004). Phosphatidylcholine lipids with
arachidonic acid esterified in the sn2 position are predominantly found in the nuclear
membrane. This increased membrane fluidity of the nuclear membrane is thought to be one of
the key determinants for 5-LOX localizing (Kulkarni, Das et al. 2002). 5-LOX rests in the cytosol
or nucleoplasm and upon activation is targeted to the nuclear membrane for substrate
acquisition and catalysis.
The Ca2+ release not only activates 5-LOX, but Ca2+ also binds to cPLA2 and targets it to
the membrane. Similar to 5-LOX, cPLA2 has a C2 domain that binds calcium and targets the
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enzyme to translocate to a region of the nuclear membrane rich in unsaturated phospholipids
(Fig 4). cPLA2 is the main phospholipase that liberates AA for the production of prostaglandins,
leukotrienes and platelet-activating factor (Dessen, Tang et al. 1999). The main substrate for
human 5-LOX is AA, and it is normally found esterified in the nuclear membrane. Free AA is not
normally available due to phospholipid reacylation. This reacylation process for AA is thought to
to be catalyzed in-part by the enzyme lysophospholipid:acyl-CoA acyltransferase (LAT) (Zarini,
Gijon et al. 2006). cPLA2 is the only phospholipase of the 15 groups of phospholipases that is
highly selective for AA esterified in the sn2 position of 1-palmitoyl-2-arachidonoyl-sn-

Figure 4. Structure of cytosolic phospholipase A2. Cytosolic phospholipase A2 (Protein Data
Bank accession code, 1CJY) is rendered in cartoon and colored in rainbow coloring blue (Nterminal) to red (C-terminal). The N-terminal β-barrel domain is a C2 domain (shades of blue)
with two bound calcium ions represented as yellow spheres. The C-terminal domain is mainly αhelical and is where the serine228 and aspartate549 catalytic dyad reside.
9

glycerophosphocholine (Clark, Lin et al. 1991). If LAT is inhibited with the organomercury
compound thimerosal so that reacylation of AA is limited, an increase of LTB4 production is
observed upon cell activation with fMLP (Zarini, Gijon et al. 2006). 5-LOX and cPLA2 act in a
concerted manner upon cell stimulation, and together increase the production of the
inflammatory LTs.

Lipid Hydroperoxides and Catalysis
The lipoxygenase catalytic cycle begins by activation of the resting state of the ferrous
(Fe2+) iron to the oxidized ferric (Fe3+) form. This enzyme activation is accomplished by trace
lipid hydroperoxides in the cell (Smith and Lands 1972; Schilstra, Veldink et al. 1992). Both
purified 5-LOX and 5-LOX in crude cell lysate were observed to have a catalytic lag phase after
addition of exogenous AA, and addition of lipid hydroperoxides shortened this lag phase both in
vivo and in vitro (Riendeau, Denis et al. 1989). The ferrous iron in the resting state is
coordinated by highly conserved histidines and the C-terminal carboxylate. Water was
determined to occupy the free sixth position of the octahedrally-coordinated ferrous iron by
high resolution x-ray crystallography studies of the soybean lipoxygenase L-1 (Minor, Steczko et
al. 1996). The Fe2+ reduces the lipid hydroperoxide generating a Fe3+ with a hydroxide ion now
supplanted as the sixth coordination ligand (Fig 5a) (Chasteen, Grady et al. 1993; van der Heijdt,
Schilstra et al. 1995). Arachidonic acid can now enter the 5-LOX active site where the proS
hydrogen on C7 is positioned and removed in a regio- and stereo-specific manner. The electron
from the proS hydrogen enters the d-orbitals of Fe3+, and proS H+ proton is trapped on the
hydroxide ion through a proton-coupled electron transfer (Fig 5b) (Schneider, Pratt et al. 2007),
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resulting in the reduction to Fe2+ (Vahedi-Faridi, Brault et al. 2004). The arachidonic acid now
has a pentadienyl radical from the hydrogen abstraction, and the radical electron is delocalized
from C5 to C9. The molecular oxygen is inserted in an antarafacial (occurring on opposite faces
from where the hydrogen abstraction occurred) addition on C5 (Fig 5c). Lipoxygenase names
are based on the regio- and stereo-specific position oxygen is inserted on arachidonic acid or
other polyunsaturated fatty acid. Control of oxygenation is what makes each LOX isozyme and
product unique (Fig 6). The Fe2+ can now donate an anion to the O2 positioned on the

Figure 5. 5-lipoxygenase reaction mechanism. From the activation of iron by lipid
hydroperoxides (LOOH) to the oxygenation of AA by 5-LOX, the iron center switches redox
states multiple times in the production of 5-HpETE (Murphy and Gijon 2007).
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Figure 6. Lipoxygenase oxygenation rules. (A) Arachidonic acid has three reactive pentadiene
moieties with a possibility of six different hydrogens available for radical abstraction. The
methylene carbons of the pentadienes are each colored a specific color with the possible
oxygenation products for each pentadiene colored similarly. (B) The central C7 of the first
pentadiene of AA is highlighted for detailed analysis. If the ProS hydrogen of the methylene
carbon lies proximal to the Fe2+ hydroxide anion and is removed, the antarafacial addition rules
state that the oxygenation products can either be 5S or 9R. If the pentadiene is flipped and the
ProR hydrogen is removed, 9S and 5R products are the possible oxidation sites. The geometric
requirements indicate that 5-LOX must have inverse entry of AA compared to the 8R-LOX and
15S-LOX-1.
arachidonic acid (Fig 5d). The O2 then traps the hydrogen from the Fe2+-H2O allowing the 5(S)hydroperoxyeicosatetraenoic acid (5-HpETE) to release and concomitantly the iron is restored
to a catalytically primed Fe3+-OH- (Fig 5e).
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The production of LTA4 from the 5-HpETE intermediate utilizes the same active site as
the first reaction of 5-LOX with a similar catalytic cycle repeated. This time the proR hydrogen is
abstracted from the C10 of 5-HpETE, and a hexatrienyl radical is formed (Shimizu, Izumi et al.
1986). The electron radical positions near C6 where the lipid hydroperoxide lies. The Fe2+
donates an electron, and the oxygen-oxygen bond is broken homolytically between the
hydroperoxide forming the triene epoxide LTA4 and a free hydroxide anion. This free hydroxide
anion can then abstract a hydrogen from the water on the sixth position of the resting Fe2+-H2O
and restore it to the catalytically active Fe3+-OH- (Murphy and Gijon 2007). 5-LOX is the only
enzyme known to have both the dioxygenase and hydrolase reactions to form the LTA 4.
Positioning of the correct pentadiene of AA and controlling which carbon is oxygenated after
hydrogen abstraction is unique to each LOX isozyme. Oxygenation of AA in a non-enzymatic
reaction yields six different regio-specific possibilities and two stereospecific conformers for
each regio-isomer, yielding a total of twelve possible single-oxidation products. LOX’s are
thought to control this oxygenation by correct pentadienyl selection along with antarafacial
addition of O2 positioned by a sterically shielded cavity or channel (Schneider, Pratt et al. 2007).

5-LOX Inactivation
Programmed obsolescence or auto-inactivation of 5-LOX can be subdivided into two
mechanisms, structural instability and turnover-based suicide inactivation. 5-LOX lability is an
important part of 5-LOX biology and inactivation could be one way of limiting production of
pro-inflammatory LTs. Overproduction of LTs could play pivotal roles in chronic inflammatory
diseases such as rheumatoid arthritis (Gheorghe, Korotkova et al. 2009), and limiting the
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stability of the enzyme is one way to combat constitutive production of LTs. Purified 5-LOX was
observed to be extremely unstable with a half-life of 24 hours at 2°C (Ueda, Kaneko et al. 1986).
This non-turnover dependent mechanism of inactivation is probably due to oxidative
destruction of the iron center (Werz 2002) and even loss of the iron (Percival 1991). 5-LOX is
thought to have an iron center accessible to non-specific oxidants including reactive oxygen
species (ROS), hydrogen peroxides and lipid hydroperoxides, and exposure to these oxidants
could cause loss of the catalytic iron (Percival, Denis et al. 1992). Incubation of 5-LOX with
reducing agents such as DTT and GSH or peroxide scavengers such as catalase, superoxide
dismutase and glutathione peroxidase have been shown to increase the half-life of 5-LOX (FordHutchinson, Gresser et al. 1994; Zhang, Hamberg et al. 1994). A protein binding partner of 5LOX was discovered in a yeast two hybrid screen where 5-LOX was used as the bait protein.
Coactosin-like protein (CLP) was discovered and direct interactions with 5-LOX were shown
later in vitro. CLP is a 16 kDa protein that resembles coactosin, a protein that interacts with
actin filaments in Dictyostelium discoideum (Provost, Samuelsson et al. 1999; Provost, Doucet
et al. 2001). Data have shown that CLP increases the production of LTs and prevents 5-LOX from
non-turnover dependent inactivation (Esser, Rakonjac et al. 2010).
The other method of inactivation is turnover-based suicide inactivation, which occurs
during 5-LOX catalysis. The half-life of purified 5-LOX in the presence of Ca2+, arachidonic acid,
phosphatidylcholine vesicles and air-saturated buffer was measured to be ~30 seconds (De
Carolis, Denis et al. 1996). The radical chemistry required for 5-LOX catalysis could irreversibly
modify the iron via the hydroperoxide intermediates (Radmark 2002), but no known proteinadduct products have been isolated. Both products of 5-LOX, 5-HpETE and LTA4, have been
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shown to irreversibly inactivate 5-LOX (Aharony, Redkar-Brown et al. 1987; Lepley and
Fitzpatrick 1994). The lipid peroxide and the electrophilic epoxide are highly reactive products,
and these metastable molecules near a highly reactive iron prove deleterious to LT formation.
Despite turnover and non-turnover based inactivation of 5-LOX, LT biosynthesis still occurs, and
these proinflammatory products have substantial effects on disease states in humans. The fact
that a labile enzyme with multiple modes of inactivation generates enough product for systemic
signaling is possibly a consequence of sequestering multiple biosynthetic enzymes to distinct
compartments. The downstream mediators of LT biosynthesis, LTB4 and LTC4, exert their effects
at nanomolar concentrations allowing for small amounts of signal to be amplified into
multicellular responses and tissue remodeling.

ATP Stimulation
Addition of ATP to crude cell lysates of guinea pig peritoneal polymorphonuclear
leukocytes enhanced 5-LOX activity (Ochi, Yoshimoto et al. 1983). This stimulatory effect on the
crude cell lysates was only seen in the presence of Ca2+, further reinforcing the importance of
membrane binding for 5-LOX activity (Aharony and Stein 1986). The Kd values for ATP binding
varied between 30-100 µM for crude extracts of 5-LOX (Furukawa, Yoshimoto et al. 1984; Ueda,
Kaneko et al. 1986). For in vitro studies of 5-LOX, Ca2+ was not required for ATP stimulation of
catalysis with exogenous substrate, and 100 µM ATP provides a maximum activation of 5-LOX
(Skorey and Gresser 1998). ATP affinity columns have been utilized for purification of 5-LOX
from rat neutrophils and heterologous expression systems (Zhang, Hammarberg et al. 2000).
However, labeling studies with reactive ATP-analogues have had limited success. The
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stoichiometry of ATP to 5-LOX was measured to be 1:1, but two different tryptophans (Trp75
and Trp201) were labeled by 2-azido-ATP. These tryptophans are not proximal to one another,
and subsequent studies with site-directed mutagenesis of these residues revealed nondeleterious effects on ATP binding (Okamoto, Hammarberg et al. 2005). 5-LOX also was found
to be non-discriminatory with respect to different nucleotides and is stimulated by nonhydrolyzable ATP mimics (Noguchi, Miyano et al. 1996). 5-LOX does not hydrolyze ATP, but ATP
has been shown to stabilize purified 5-LOX and increase the production of 5-HPETE.

Phosphorylation
5-LOX has been reported to be phosphorylated on three different serine residues
including Ser271, Ser523 and Ser663 by the mitogen-activated protein kinase-activated protein
kinase (MAPKAP), protein kinase A (PKA) catalytic subunit, and extracellular signal-regulated
kinse 2 (ERK2), respectively (Werz, Klemm et al. 2000; Werz, Szellas et al. 2002; Werz and
Steinhilber 2006). Extracellular signals cause phosphorylation events inside the cell, thus,
transducing signals that result in redistribution of many cytosolic enzymes and transcription
factors. 5-LOX and cPLA2 are both affected by phosphorylation events that also elevate
intracellular Ca2+; hence they are coordinated for maximal response. Phosphorylated 5-LOX was
first found in the nucleus of HL60 cells that were ionophore stimulated (Lepley, Muskardin et al.
1996). If tyrosine kinase inhibitors were added to the ionophore challenged HL60 cells, 5-LOX
did not translocate to the nuclear membrane or efficiently synthesize leukotrienes. Later fMLPchallenged neutrophils with an inhibitor of MAPKAP kinase were tested. The 5-LOX neither
translocated to the nuclear membrane nor produced leukotrienes. In in-gel kinase assays, it was
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shown that 5-LOX is a substrate for p38 MAPK-regulated MK2 and MK3 at Ser271. p38 MAPK is
involved in adhesion, chemotaxis, degranulation and oxidative burst and can be activated by
many inflammatory stimuli including Ca2+ mobilizing agents, phorbol esters, chemotactic
factors, osmotic shock, genotoxic stress and heat shock (for review see (Werz 2002).
Interestingly, 5-LOX activity was upregulated in stress-simulated leukocytes in the presence of
Ca2+ chelators. This Ca2+ free stimulation of leukotriene biosynthesis allows for differential
control of inflammation by MAPK-mediated phosphorylation events (Radmark and Samuelsson
2010).
Ser663 of 5-LOX was shown to be phosphorylated by a different MAP kinase, extracellular
signal-regulated kinase 2 (ERK2), and addition of unsaturated fatty acid stimulates this
phosphorylation (Werz, Burkert et al. 2002). Like p38 MAP kinase activity, ERK2 was shown to
stimulate 5-LOX activity in the absence of ionophore in phorbol myristate acetate (PMA) primed
cells. Without PMA-priming in Mono Mac 6 cells, 5-LOX did not translocate to the nucleus even
in the presence of ionophore. This supports the idea that multiple 5-LOX activation events are
responsible for optimal leukotriene production (Werz, Klemm et al. 2001). Upregulation of ERK2
by the androgen 5α-dihydrotestosterone (5α-DHT) causes nuclear localization of 5-LOX in nonCa2+-activated cells (Pergola, Dodt et al. 2008). The subcellular location of phospho-Ser663 5-LOX
at the nuclear membrane in the absence of Ca2+ signal decreases the amount of LT formation
upon ionophore challenge, and treatment of female neutrophils with male levels of 5α-DHT
suppresses 5-LOX product synthesis. Epidemiological studies of asthma patients report higher
incidence of the disease in prepubescent boys and women of all ages. Once young men hit

17

puberty and 5α-DHT production is increased, asthmatic episodes decline (Almqvist, Worm et al.
2008).
The last documented site of 5-LOX phosphorylation is at Ser523 (Luo, Jones et al. 2005).
The cAMP-depedent Protein Kinase (PKA), which is controlled by cAMP levels, is responsible for
phosphorylation of 5-LOX at Ser523, and modification of this Ser reduces the activity of 5-LOX
(Luo, Jones et al. 2004). The phosphorylated Ser523 is thought to control 5-LOX catalysis through
an allosteric regulation site. This Ser523 lies near a nuclear location sequence (NLS) on 5-LOX,
and upon phosphorylation, the enzyme’s ability to relocate to nucleus is inhibited. Hence,
phosphorylation of Ser523 appears to be a deactivation mechanism for LT biosynthesis. PKA
mediated phosphorylation of Ser523 is inhibited by addition of polyunsaturated fatty acids in
neutrophils with an increase in 5-LOX translocation and product formation (Flamand, Lefebvre
et al. 2006). A second binding site for AA has been reported on 5-LOX that allosterically
regulates the enzyme, and the inhibitor acetyl-11-keto-β-boswelic acid (AKBA) is thought to
inhibit at this allosteric site (Poeckel, Tausch et al. 2006). The polyunsaturated fatty acid may
bind at the allosteric binding site precluding an interaction with PKA. These three
phosphorylation sites of 5-LOX add another level of control to LT biosynthesis and could be key
determinants for cell-specific activation of 5-LOX for production of a particular downstream LT
effector.
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Five-Lipoxygenase-Activating Protein
Scientists at Merck-Frosst contemporaneously with scientists at Bayer discovered the
drugs MK-886 and Bay X1005, respectively, that inhibit leukotriene biosynthesis without
affecting 5-LOX, cPLA2, or activities that function through non-selective inhibitory mechanisms.
The lowered 5-HpETE production by the above drugs did not occur after cells were subjected to
lysis or after purification of 5-LOX. To determine how MK-886 inhibits leukotriene production,
scientists at Merck designed a photoaffinity analogue of MK-886 and a MK-886 affinity gel for
identification of this unknown protein (Gillard, Ford-Hutchinson et al. 1989). An 18 kDa integral
membrane protein that bound to MK-886 analogues was identified and called 5-lipoxygenaseactivating protein (FLAP) (Dixon, Diehl et al. 1990; Miller, Gillard et al. 1990). This protein is
required for cellular activity of 5-LOX, and inhibition of FLAP limits the production of
leukotrienes in intact cells (Evans, Ferguson et al. 2008). Upon Ca2+ stimulation, 5-LOX is
thought to dock at the membrane next to FLAP where a protein-protein mediated handoff of
AA from FLAP to 5-LOX occurs (Plante, Picard et al. 2006). The indole and quinolone inhibitors
of FLAP bind between the protomers of the trimeric FLAP where AA is thought to bind. FLAP has
been shown to enhance both the dioxygenation of AA and the dehydration of 5-HpETE by 5-LOX
(Mandal, Skoch et al. 2004). FLAP is a member of the membrane-associated proteins in
eicosanoid-and-glutathione metabolism (MAPEG) superfamily and is the only member not to
bind GSH or have enzymatic activity. FLAP lacks the conserved side chains necessary for GSH
binding that all other MAPEG member’s utilize. FLAP is an AA-binding protein that sequesters
substrate for 5-LOX while acting as a membrane anchor for 5-LOX. Increased expression levels
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of FLAP correlate with the increased amounts of leukotrienes being produced; without FLAP
there is no cellular leukotriene synthesis from endogenous arachidonic acid.

Figure 7. Structure of 5-lipoxygenase-activating protein. Cartoon representation of trimeric
FLAP (Protein Data Bank accession code, 2Q7R) with each protomer colored in red, blue or
green. FLAP is a transmembrane protein that is essential for leukotriene biosynthesis in intact
cells. The competitive inhibitor of AA binding, MK-591 shown as yellow sticks, is located
between protomers of FLAP in a membrane-embedded pocket. Cytosolic or nucleoplasmic
loops are positioned at the top of the model and are thought to be key determinants for 5-LOX
binding.
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The crystal structure of FLAP was solved to 4.0 Å in the presence of MK-591 (Ferguson,
McKeever et al. 2007). FLAP crystallized as a trimer with the competitive inhibitors to AA
between each protomer in membrane-embedded pockets (Fig 7). Each monomer of FLAP
consists of four transmembrane spanning helices with the N- and C-termini located on the same
side of the membrane in the perinuclear space. The MK-591 inhibitor bound in a membrane
groove between helix α1 of one protomer and helix α4 of the adjacent protomer. The cytosolic
surface loops of FLAP that connect helices α1 to α2 and helices α3 to α4 are highly conserved
from Danio rerio to Homo sapiens and could be important for contacting 5-LOX and anchoring it
to the membrane.

Downstream Enzymes of Leukotriene Biosynthesis
5-LOX, cPLA2 and FLAP have been introduced as enzymes crucial in the production of
leukotrienes, but the true effectors of human physiology are the downstream products formed
by later enzymes. Bifurcation of leukotriene biosynthesis occurs after 5-LOX catalysis, and these
enzymes that metabolize the 5-LOX product control the pro-inflammatory state of the organism
(Peters-Golden and Henderson 2007). There are two enzymatic fates of the 5-lipoxygenaseproduct LTA4; conjugation with a reduced form of GSH by LTC4 synthase or regio-specific
hydrolysis by LTA4 hydrolase to form LTB4. These products can either be formed in the same
cell with 5-LOX or can occur through transcellular biosynthesis (Folco and Murphy 2006). One
example of transcellular biosynthesis occurs in endothelial cells, which have no reported 5-LOX
activity, but receive LTA4 from a neutrophil and metabolize the donated LTA4 into LTC4. The
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majority of leukotriene products come from leukocytes, but transcellular biosynthesis allows
for another level of control in terms of which pro-inflammatory leukotriene is manufactured.

Leukotriene C4 Synthase
The products referred to as the slow reacting substance of anaphylaxis (SRS-A) are
produced by the enzyme LTC4 synthase. This enzyme falls in the same class of proteins as FLAP,
the MAPEG family. Like FLAP, LTC4 synthase is a trimeric four helix bundle transmembrane
protein, but LTC4 synthase both binds GSH and has enzymatic activity. The LTC4 synthase
structure was first published in 2007 and was reported by two separate groups in the same
issue of Nature (Ago, Kanaoka et al. 2007; Martinez Molina, Wetterholm et al. 2007). The
structure presented by Molina et al. was at higher resolution, (Protein Data Bank accession
code, 2UUI) and the protein was crystallized in the presence of GSH and a detergent molecule
thought to be mimicking the substrate LTA4 (Protein Data bank accession code, 2UUH). The GSH
binding site lies in a deep portion of the groove between helices α1 and α4 from neighboring
protomers. The detergent dodecyl maltoside (DDM) lies superficial to the GSH but penetrates
deeper along the surface of the protein into the membrane bilayer (Fig 8). FLAP and LTC4
synthase are thought to bind their respective substrate deep in the membrane bilayer
suggesting that it is acquired by lateral diffusion. The arrangement of GSH and DDM with the
GSH lying deeper inside the membrane embedded pocket with the detergent sitting on-top of
the GSH subsite led to the idea that GSH binds first and induces a conformational change
conducive for LTA4 binding. However, previous kinetic data for this enzyme along with other
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MAPEG proteins are consistent with a random substrate-binding order (Gupta, Gresser et al.
1998).

Figure 8. Structure of leukotriene C4 synthase. Cartoon representation of transmembrane LTC4
synthase crystallized as a trimeric protein with each monomer colored orange, blue or pink,
respectively. The cytosolic side is on top. DDM is shown as green sticks and glutathione as
yellow sticks with standard coloring for other elements. The DDM binds on top of the GSH
subsite and is thought to mimic the natural substrate LTA4. Both DDM and LTA4 are thought to
bind in a membrane-buried groove between different protomers with the long carbon tail
penetrating the membrane.
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LTC4 synthase conjugates GSH to LTA4 by attack of the anionic thiolate of GSH on the
allylic C6 oxirane ring of LTA4 (Lewis, Austen et al. 1980; Lewis, Drazen et al. 1980; Martinez
Molina, Eshaghi et al. 2008). The product made is LTC4, which is exported out of the cell by
multidrug resistance-associated protein 1(MRP-1) where it can undergo proteolytic hydrolysis
to form LTD4 then LTE4. These cysteinyl leukotrienes compromised of LTC4, LTD4 and LTE4, exert
their effects at nanomolar concentration ranges in the respiratory tract and microcirculation by
binding to the G-protein coupled receptors CysLT1/CysLT2 (Dahlen, Hedqvist et al. 1980; Dahlen,
Bjork et al. 1981; Hanna, Bach et al. 1981; Weiss, Drazen et al. 1982). A third CysLT3 receptor
has been identified without known biological function, and multiple agonist have shown to
elicit the G-protein coupled response (Evans, Ferguson et al. 2008). LTE4, which is the least
active of the cysteinyl leukotrienes, is the only cysteinyl leukotriene that can be measured
quantitatively in plasma and urine (Drazen, O'Brien et al. 1992; Kumlin, Stensvad et al. 1995).

Leukotriene A4 Hydrolase
The product of the 5-LOX reaction is also the substrate for LTA4 hydrolase. This soluble enzyme
converts LTA4 into LTB4 by epoxide hydrolysis and thus provides an alternative fate for the
product of the 5-LOX reaction. LTB4 is a very potent lipid mediator that promotes chemotactic
and chemokinetic behavior of human polymorphonuclear monocytes at sub-nanomolar
concentrations (Radmark, Malmsten et al. 1980). The crystal structure of LTA4 hydrolase
confirmed the prediction from sequence alignments that it is a member of the M1 amino
peptidase superfamily (Thunnissen, Nordlund et al. 2001; Thunnissen, Andersson et al. 2002).
These are zinc-containing amino peptidases typified by thermolysin. However, LTA4 hydrolase is
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roughly double the size of thermolysin, as it contains two additional domains: an all-β-domain
at the N terminus and an α-helical domain at the C terminus (Fig. 9). These two domains extend
from the thermolysin-like core to close over what would be the exposed peptide-binding site in
an M1 peptidase. The triangular arrangement of the three domains allows access to the
catalytic zinc via a central channel. In addition to the hydrolase activity, the enzyme also has
peptidase activity, but a biological role for the peptidase activity remains to be fully identified.

Figure 9. Structure of leukotriene A4 hydrolase. Cartoon representation of the heterotrimer
LTA4 hydrolase with the thermolysin-like (M1 peptidase) core shown as wheat, N-terminal
domain shown as green and C-terminal domain shown as purple (Protein Data Bank accession
code, 1HS6). The catalytic zinc is illustrated as a gray sphere, and substrate binding occurs
through a channel between the two flanking domains.
Recent data suggest that the aminopeptidase activity cleaves and inactivates the
peptide Pro-Gly-Pro. This intact peptide is proinflammatory and cleavage could aid in the
resolution of inflammation (Helgstrand, Hasan et al. 2010). LTA4 hydrolase is classified a
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moonlighting protein because of its abilities to perform two different catalytic activities in one
polypeptide chain. Even more unique is that LTA4 hydrolase performs both catalytic activities
with the same zinc cofactor with distinct but overlapping binding sites for each substrate
(Jeffery 2003; Helgstrand, Hasan et al. 2010). It is interesting to note that the LTA4 hydrolase“modified” M1 peptidase structure is not unique to an enzyme of the LT biosynthetic pathway.
A similar structure has been described for a cold-active amino peptidase from Colwellia
psychrerythraea (Bauvois, Jacquamet et al. 2008).

Membrane Compartmentalization
Leukocytes must cycle between pro-inflammatory and anti-inflammatory states and the
control of these states is multi-faceted. Leukotriene formation is held dormant by solubilization
of 5-LOX and cPLA2 in the cytosol until an activation signal clusters sequential catalytic activities
at the membrane. This assemblage of LT enzymes is thought to provide a mechanism to
enhance biosynthetic efficiency. The proteins of the LT biosynthetic pathway are found in the
nucleoplasm, cytoplasm, inner and outer nuclear membranes, and extracellular space and, as a
result, are not all free to reversibly cluster. In addition, some steps in the pathway that further
modify the LTs are transcellular (Zarini, Gijon et al. 2009). Consequently, regulation of pathway
flux can be executed by the subcellular targeting of key enzymes. For example, targeting of 5LOX to the outer nuclear membrane is thought to promote the formation of the cysteinyl-LTs,
whereas 5-LOX targeting to the inner nuclear membrane results in the production of LTB4
(Thunnissen, Nordlund et al. 2001; Thunnissen, Andersson et al. 2002).
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The LTC4 synthase and LTA4 hydrolase activities represent a bifurcation of the LT
biosynthetic pathway: the former directs the 5-LOX product into the production of cysteinyl-LTs
such as LTC4 and LTD4 and the latter to LTB4. These LTs are distinct in the biological responses
they trigger; thus, an intriguing aspect of the regulation of LT biosynthesis is how the relative
rates of cysteinyl-LT and LTB4 production are controlled. Compartmentalization of enzyme
activities has been proposed to play a significant role in the regulation of LT production. Prior to
activation, 5-LOX can reside in the cytoplasm or the nucleus (due to the presence of multiple
nuclear location sequences (Jones, Luo et al. 2002; Jones, Luo et al. 2003)); furthermore, its
cellular location is dynamic and can vary with cell type. One mechanism of control of 5-LOX
location is phosphorylation. For instance, phosphorylation of Ser271 interferes with the export of
5-LOX from the nucleus, (Flamand, Luo et al. 2009) and phosphorylation on Ser523 impairs
nuclear import. Thus, cell stimulation results in the Ca2+-dependent targeting of 5-LOX to the
inner and/or outer nuclear membrane(s), depending upon the compartment(s) in which the
unstimulated enzyme resides.

Recall that 5-LOX is presented its substrate by its helper protein FLAP, located in the
nuclear membrane. Although FLAP is not required for 5-LOX activity or its translocation to the
membrane in vivo, the cellular capacity for LT synthesis correlates with FLAP expression
(Bennett, Buckley et al. 1982; Bennett, Chiang et al. 1993; Coffey, Wilcoxen et al. 1994).
Furthermore, inhibitors of FLAP are effective inhibitors of LT production (Evans, Ferguson et al.
2008). MK-591, the drug with which FLAP was crystallized, inhibits LT biosynthesis through
binding to FLAP. Recall also that LTC4 synthase is a membrane protein structurally similar to
FLAP. However, in contrast to FLAP, which is distributed on both the inner and outer nuclear
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membranes, LTC4 synthase is restricted to the outer nuclear membrane (Christmas, Weber et
al. 2002). Studies by Mandal et al. (Mandal, Skoch et al. 2004) revealed two populations of FLAP
in the nuclear membrane: FLAP that is unassociated and FLAP that is associated with LTC 4
synthase. Because FLAP is more abundant than LTC4 synthase, there is no LTC4 synthase that is
not in complex with FLAP. The authors proposed the existence of two pools of FLAP, one to
channel LTA4 to the synthase and the other to allow access to the LT by LTA 4 hydrolase. In
subsequent work, the authors demonstrated activation-dependent assembly of a complex of 5LOX and FLAP (Mandal, Jones et al. 2008). In their model, the outer nuclear membrane complex
is composed of 5-LOX, FLAP, and LTC4 synthase, whereas on the inner membrane, which is
devoid of the synthase, the complex consists of 5-LOX and FLAP. Interaction of FLAP with both
LTC4 synthase and 5-LOX has been suggested by others (Strid, Svartz et al. 2009).

The proposed AA-binding site in FLAP is deep within the hydrophobic region of the
bilayer. This placement appears to preclude a direct interaction between the donor- and
acceptor-binding sites and suggests that accessibility to FLAP-bound AA by 5-LOX is limited,
even when the enzyme is membrane-bound. The only part of 5-LOX demonstrated to penetrate
the bilayer is the putative membrane insertion loop that contains Trp75 in the C2-like domain.
Thus, 5-LOX is tethered to the membrane with calcium activation and possibly further anchored
by interactions with FLAP, but 5-LOX’s substrate is bound deep within the hydrophobic bilayer
to the helper protein FLAP. How the AA travels from its position in the bilayer to the catalytic
domain of LOX, which does not localize to the membrane in the absence a functional C2-like
domain, is unknown. The entrance to the active site is roughly in the middle of the catalytic
domain, ∼30 Å removed from the C2-like-catalytic domain interface. Thus, direct passage of
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substrate from the bilayer to the active site of the soluble enzyme (as occurs in some
monotypic membrane-associated enzymes (Forneris and Mattevi 2008)) can occur only if the
catalytic domain abuts the membrane. A green fluorescent protein-labeled catalytic domainonly construct does not translocate to the nuclear membrane under conditions that mobilize
the similarly tagged C2-like domain (Chen and Funk 2001). However, this observation does not
rule out an association of the catalytic domain with the membrane once it is tethered by the
C2-like domain. Another aspect of substrate transfer to consider is the orientation of AA in
FLAP. The structures of both FLAP and LTC4 synthase suggest that AA and LTA4 bind with the
hydrophobic tails innermost in the membrane and the carboxylate groups at the membrane
surface. This may require that the initial interaction of 5-LOX with FLAP-bound AA is via the
substrate carboxylate. Such a transfer mechanism might utilize a positively charged amino acid
at the entrance to the active site. To the contrary, the carboxylate of AA could be protonated
and situated deep inside the membrane with an upside-down orientation with respect to the
fatty acids esterified in the phospholipids. 5-LOX would then have to recognize the hydrophobic
tail of AA. FLAP could facilitate release of AA to the anchored 5-LOX by deprotonating the
carboxylate group on AA. Ions are not normally positioned in the membrane bilayer, and the
negatively charged carboxylate on AA could behave similarly to other anions after
deprotonation.

LTA4 hydrolase, the alternative enzyme that metabolizes LTA4, is a soluble enzyme found
in the nucleus and cytoplasm (Brock, Maydanski et al. 2001). Its distribution between these
compartments is dynamic (Brock, Lee et al. 2005). Luo et al. (Luo, Jones et al. 2003) have shown
that the cellular capacity for the synthesis of LTB4 correlates with the capacity for import of 529

LOX into the nucleus. Thus, the exclusion of LTC4 synthase from the inner nuclear membrane
and the presence of the hydrolase in the nucleus result in a pool of LTA 4 that does not have
access to the cysteinyl-LT biosynthetic branch of the bifurcation but is available only to the
hydrolase (Fig 10). If LTC4 were not excluded from the inner nuclear membrane in cells
expressing both LTC4 synthase and LTA4 hydrolase, the transmembrane synthase would have
preferential access to substrate due to its proximity to FLAP and consequently 5-LOX. The

Figure 10. Early leukotriene biosynthetic pathway. Leukotriene biosynthesis is stimulated by
Ca2+ influx into the cell where cPLA2 (gray) targets to the nuclear membrane and liberates
arachidonic. 5-LOX (pink) is stimulated by the same Ca2+ and is targeted to the membrane
where it docks next to FLAP (blue) and receives AA that has been sequestered by FLAP. 5-LOX
performs a two-step reaction to produce LTA4 from AA. LTC4 synthase (brown) exists only on
the cytosolic side of the nuclear membrane and has been shown to interact with 5-LOX and
FLAP directly. This close association of 5-LOX, FLAP and LTC4 synthase shows how sequestering
of biosynthetic enzymes helps produce more efficiently the LTs. Inside the nucleus, only pools
of FLAP have been observed and LTB4 production is favored by nuclear localized LTA4 hydrolase
(green).

30

hydrophobic LTA4 in the membrane phase. The half-life of LTA4 is ∼10 s in aqueous milieu but is
significantly extended in the presence of phospholipids (Fiore and Serhan 1989). As a
consequence, even the chemical nature of the phospholipid bilayer favors the LTC4 synthase
reaction over that of the hydrolase, as the substrate need not enter an aqueous environment,
where it is susceptible to non-enzymatic hydrolysis.

The bifurcation of the LT biosynthetic pathway after the production of LTA4 contributes
to the production of LTs of diverse structures and functions. Lability of the pathway
intermediate LTA4 could also play a major role in the amount and which LTs are produced.
Phospholipids and fatty acid-binding proteins have been shown to help stabilize LTA4, and how
these proteins or phospholipids present the substrate to LTA 4 hydrolase or LTC4 synthase could
affect the production of LTs. Another interesting facet includes how downstream events in one
pathway branch can have an effect on the flux through the alternative branch. LTC 4 is exported
from the cell by the membrane pump known as MRP-1; in mice lacking the multidrug export
pump, LTB4 synthesis is increased. The interpretation of this result is that LTC4 accumulation
inhibits LTC4 synthase activity by a feedback mechanism, and thus, more LTA4 is available for
metabolism by the hydrolase (Schultz, Wijnholds et al. 2001). The export of LTB4 is known to be
a carrier-mediated process, but no known export protein has been identified (Lam, Gagnon et
al. 1990).
The initial step in LT synthesis is catalyzed by the Ca2+-dependent membrane-binding
enzyme 5-LOX. 5-LOX is translocated to the nuclear membrane contemporaneously with cPLA2,
and whether 5-LOX is located on the inner or outer nuclear membrane appears to help
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determine the fate of its product, LTA4. Thus, at an early step in LT biosynthesis,
compartmentalization is an important determinant in pathway flux within the branches of this
intricate biosynthetic pathway for lipid mediators. Furthermore, compartmentalization can be
regulated by post-translational modifications such as phosphorylation that control the import
and export of 5-LOX from the nucleus or position it more strictly at the membrane. There are
multiple players in the control of LT synthesis from the release of AA from its esterification in
the membrane to the export of the eicosanoid products out of the cell into the specific tissue
where their effects are exerted through specific GPCRs.

Cell Types and Inflammation
The study of mammalian enzymes and how effects of product are played throughout
the organism requires an understanding of the intercommunication of multiple cell types and
different tissues. Human 5-LOX and the other enzymes involved in LT biosynthesis are
expressed in many different cell types and have been isolated from multiple disease-state
tissues. 5-LOX expression occurs mainly in cells of myeloid origin, including polymorphonuclear
leukocytes (PMNL), granulocytes, monocytes/macrophages, neutrophils, mast cells, Blymphocytes and dendritic cells, for review (Werz 2002; Radmark and Samuelsson 2007). 5-LOX
expression along with the expression of FLAP, LTA4 hydrolase, LTC4 synthase and the LT
receptors CysLT1, CysLT2, BLT1 and BLT2 has been observed in macrophage/foam cells of
atherosclerotic lesions. An increased expression level of 5-LOX in the atherosclerotic lesion has
a direct link to more advanced stages of atherosclerosis and plaque instability, which can lead
to myocardial infarction and death (Qiu, Gabrielsen et al. 2006).
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Leukocytes are inflammatory cells from the immune system that combat bacteria,
fungi, parasites and other foreign matter. However, a hypersensitivity response to various
allergens sometimes occurs, and this excessive activation of the leukocyte that can manifest
into specific autoimmune diseases. LTs produced by 5-LOX are local-acting messengers of
inflammation and have been implicated in innate and adaptive responses to stimuli (Poeckel
and Funk 2010). The LTs act in a concerted effort in innate immunity and can recruit virtually all
subgroups of leukocytes to sites of inflammation, for review (Peters-Golden and Henderson
2007). The pathogenesis of asthma, cardiovascular disease (CVD) and cancer requires the
accumulation of leukocytes at inflammatory sites. LTs stimulate growth of more leukocytes in
the bone marrow CD34+ pluripotent hematopoietic stem-cell progenitors. These new
leukocytes then migrate into the bloodstream where the same LT signal increases the
expression of adhesion proteins on the outside of the cell, which promotes cell motility and
transmigration into the inflamed tissue. LTB4, which interacts mainly with BLT1, recruits mast
cells, monocytes/macrophages, neutrophils and T cells; LTD4 interacts with the CysLT1 receptor
and promotes the recruitment of eosinophils, dendritic cells and T cells to sites of
inflammation. The leukocytes act in a collaborative effort at the site of inflammation with each
cell’s survival enhanced and extended by one-another’s synthesis of LTs. The LTs are also
involved in adaptive immunity by activating T helper cells 2 (Th2 cells), which compound the
immune response by release of cytokines (Robbiani, Finch et al. 2000; Okunishi, Dohi et al.
2004). Dendritic cells, which are major players in the coordination of innate and adaptive
immunity, produce the proinflammatory LTs and are considered the most professional antigenpresenting cells (APC) (Hedi and Norbert 2004). LTs have also been implicated in autoimmune
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disorders including systemic lupus erythematosus (SLE), allergic rhinitis(Peters-Golden and
Henderson 2005) and rheumatoid arthritis (Peters-Golden and Henderson 2007). LTs also have
a link to certain cancers. Malignant cells in esophageal, colorectal, and pancreatic
adenocarcinomas, melanoma, lymphomas, bronchogenic carcinoma, and leukemias have
increased expression of 5-LOX and FLAP, along with other downstream LT enzymes.
Furthermore, chronic inflammation has been observed as an important factor that increases
the incidence of cancer (Avis, Jett et al. 1996; Romano, Catalano et al. 2001). 5-LOX begins
many proinflammatory events by the initiation of LT production, and inflammation can be
linked to numerous diseases.
Different leukocyte cell types produce preferentially one type of LT product of the
bifurcation fork. All leukocytes have the 5-LOX machinery to produce LTA4 but have varying
amounts of LTC4 synthase or LTA4 hydrolase. Eosinophils, basophils and mast cells produce
mainly LTC4, whereas monocytes/macrophages and neutrophils predominantly generate LTB4
(Werz 2002). LTA4 is the precursor for the following two products and can be exported to other
cells for further metabolism. Parenchymal cell and erythrocytes are LTA4 receiving cells that are
unable to produce LTA4; however, LTB4 and LTC4 products have been isolated from these cell
types, respectively. Over 50% of the LTA4 produced inside of an activated cell is not metabolized
by that cell but is released into the extracellular milieu, which could then be used for
transcellular biosynthesis of LTs (Sala, Bolla et al. 1996; Sala, Testa et al. 1996; Sala, Folco et al.
2010).
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LTs have been implicated in various diseases, most notably asthma, cardiovascular
disease (CVD) and cancer (Funk 2011) but have also been shown to be beneficial. LTs enhance
the clearance of microbes through the upregulation of macrophages and neutrophils that
ingest and kill the microbial infection (Peters-Golden, Canetti et al. 2005). 5-LOX knockout mice
that have been intratracheally challenged with Klebsiella pneumonia had higher lethality as to
wild-type mice and also displayed lower clearance of the pathogen through phagocytic
engulfment (Bailie, Standiford et al. 1996). The LT signal can enter the interstitial fluid and
migrate to other cells for paracrine signaling. The LT signal is transduced inside structural and
inflammatory cells by specific GPCRs through G-protein switching in the cytoplasm. GDP release
and GTP uptake by the G-protein α-subunit causes a release of intracellular Ca2+ and reduction
of intracellular cAMP (Tager and Luster 2003; Kanaoka and Boyce 2004). These intracellular
signals of the LT GPCRs can activate various kinase cascades that affect cell motility and
transcriptional regulation. The LT GPCRs fall in the subfamily A5 of rhodopsin-like receptors and
are subdivided into two groups, the cysteinyl LT receptors and BLT receptors. There are two
cysteinyl leukotriene receptors for which biological function has been described. CysLT1 has
been implicated in sustained bronchoconstriction, mucus secretion and edema in the airways.
There are two antagonists, montelukast® and zafirlukast®, on the market in the United States for
CysLT1 that are approved for the treatment of asthma. LTC4 and LTD4 are the main agonist of
CysLT1. CysLT2 is not implicated in bronchoconstriction but, rather, contributes to inflammatory
events that increase vascular permeability and tissue fibrosis (Peters-Golden and Henderson
2007).

35

There have been two B leukotriene receptors discovered with BLT 1 having the most
known biological relevance. The BLT1 receptor is expressed primarily on myeloid derived cells
and signals through pertussis toxin sensitive Gi-linked chemotactic response (Funk 2001). This
Gq coupling stimulates neutrophil secretion, and immigration and activation of granulocytes.
These granulocytes then adhere to vessel walls and release superoxide lysosomal enzymes that
increase phagocytosis of neutrophils and macrophages through this degranulation process
(Claesson and Dahlen 1999; Mancuso, Nana-Sinkam et al. 2001). LTB4’s role in increased
interleukin production, and its stimulatory effect on secretion of IgE, IgG and IgM implies that is
an effector in other inflammatory diseases, such as arthritis, inflammatory bowel disease and
psoriasis. Little biological function has been attributed to the more promiscuous and less
selective BLT2 receptor, which is more ubiquitously expressed and has micromolar-affinity to
many other lipid signals. There are no market-available antagonists for the BLT1, BLT2 or CysLT2
receptors.
Transcellular biosynthesis or cell-cell interactions also lead to the rescue of
inflammation. Different cell types express different isozymes of LOX, including 12-Lipoxygenase
(12-LOX) and 15-lipoxygenase-1 (15-LOX-1). Lipoxins (LXs), which are potent anti-inflammatory
signals, are generated during multicellular host response to inflammation, and the response is
thought to require different LOX isozymes catalyzing successive and different oxygenation
reactions on AA (Serhan, Hamberg et al. 1984). LXs activate nonphlogistic phagocytosis by
macrophages of apoptotic neutrophils and other leukocytes. The first reported LX requires 15LOX catalysis to form 15(S)-HpETE and then 5(S) oxygenation by 5-LOX on the 15(S)-HpETE. 5LOX dehydrates the 5-hydroperoxide to the 5,6 epoxide-15-HETE. Specific hydrolases inside the
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cell take this unstable intermediate and form the trihydroxy tetraenes, lipoxin A4 and lipoxin B4
(Serhan 1994). Another multicellular pathway for formation of LXs utilizes 12-LOX from
platelets and 5-LOX from leukocytes (Fig 11.). The third major pathway for formation of LXs that
has been discovered involves aspirin-acetylated cyclooxygenase-2 (Serhan 2002). This modified
COX-2 generates 15(R)-HETE products from AA that are released from epithelial and endothelial
cells and are further modified through transcellular routes by leukocyte 5-LOX to form the 15epimer LXs (Claria and Serhan 1995; Herschman 1996). These 15(R)-lipoxins resist metabolic
inactivation and are considered more potent at inhibiting inflammatory responses than the
15(S)-lipoxins. The LXs are thought to elicit their biological response by binding to a specific
heptahelical G-protein coupled receptor coined the LX receptor or ALX (Chiang, Serhan et al.
2006). Subsequent studies have now shown that other agonists including peptides can activate
ALX, so there is much to be investigated in the rescue of inflammation. Without the aid of proresolving molecules such as the LXs, the anti-inflammatory state may never be reached. Carl
Nathan in an excellent Nature review, stated that “the non-inflammatory state does not arise
passively from an absence of inflammatory stimuli; rather, maintenance of health requires the
positive actions of specific gene products to suppress reactions to potentially inflammatory
stimuli that do not warrant a full response” (Nathan 2002). The balance of pro-inflammation
and anti-inflammation is a symbiotic relationship in a healthy individual, and when one
becomes favored, chronic disease can become a mainstay.
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Figure 11. Lipoxin biosynthetic pathway. LX generation is thought to require cells with
different lipid-metabolizing enzymes to interact on products of previously metabolized
dioxygenated fatty acids. One possible route of LX formation utilizes 5-LOX activity first,
followed by 15-LOX activity on the LTA4 that arrived from a transcellular source. The unstable
intermediate of 5,6-Ep-15-HETE can be enzymatically hydrolyzed to form either LXB4 or LXA4
(Chiang, Serhan et al. 2006).
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CHAPTER TWO
THE STRUCTURE OF HUMAN 5-LIPOXYGENASE
Overview
The synthesis of both pro-inflammatory leukotrienes and anti-inflammatory lipoxins
requires the enzyme 5-lipoxygenease (5-LOX). 5-LOX activity is short-lived, apparently in part
due to an intrinsic instability of the enzyme. We identified a 5-LOX-specific destabilizing
sequence that is involved in orienting the carboxy-terminus which binds the catalytic iron.
Herein we report the crystal structure at 2.4 Å resolution of human 5-LOX stabilized by
replacement of this sequence.

Introduction
Leukotrienes (LT) and lipoxins are potent mediators of the inflammatory response
derived from arachidonic acid (AA). When leukocytes are activated arachidonic acid is released
from the nuclear membrane by the action of phospholipase A2 and binds Five-LipoxygenaseActivating Protein (FLAP). The increased Ca2+ concentration of the activated cells
simultaneously promotes translocation of 5-LOX to the nuclear membrane where it acquires its
substrate from 5-lipoxygenase activating protein (FLAP) (Dixon, Diehl et al. 1990; Evans,
Ferguson et al. 2008). Arachidonic acid (AA) is converted to leukotriene (LTA4) in a two- step
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reaction which produces the 5S-isomer of hydroperoxyeicosatetraenoic acid (5S-HPETE) as an
intermediate (Shimizu, Radmark et al. 1984; Radmark and Samuelsson 2009).
Auto-inactivation of 5-LOX activity has been described, and this loss of activity is
perhaps important in limiting the synthesis of its pro- and anti-inflammatory products (Murphy
and Gijon 2007). Previous reports indicate that non-turnover based inactivation is a
consequence of an O2 sensitivity linked to the oxidation state of the catalytic iron (Percival,
Denis et al. 1992). However, not all LOXs display this hypersensitivity to O2. For example, 8RLOX activity is stable despite a solvent exposed iron coordination sphere equivalent to that in 5LOX (Neau, Gilbert et al. 2009). In similar conditions 50% of 5-LOX activity is lost in 10 hours
(Zhang, Hamberg et al. 1994). We reasoned that 5-LOX specific destabilizing features may
confer susceptibility to non-turnover based inactivation. Regulatory mechanisms that facilitate
transient activation include targeted degradation, phosphorylation, and allosteric control of
enzyme activities. Auto-inactivation as a consequence of intrinsic protein instability may play a
similar role. For example, the instability of the tumor suppressor protein p53, relative to its
orthologs such as p73, has been proposed to have a functional role (Canadillas, Tidow et al.
2006).

Results and Discussion
Based on the crystal structures of two AA-metabolizing lipoxygenases [an 8R-LOX from
Plexaura homomalla (Oldham, Brash et al. 2005; Neau, Gilbert et al. 2009) and a 15-LOX from
rabbit reticulocyte (Gillmor, Villasenor et al. 1997; Choi, Chon et al. 2008)], each with ~40%
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sequence identity to 5-LOX), we identified a 5-LOX specific lysine-rich region near the Cterminus of the enzyme that might confer instability. In the 8R- and 15-LOX structures a turn
centered on amino acid 655 (5-LOX numbering) leads from the C-terminal helix to the carboxyl
terminal segment, allowing the terminal carboxylate to penetrate the LOX body and bind the
catalytic iron (Fig 12a, 12b). In most LOXs, amino acid 655 is a highly conserved Leu, with its
side chain pointing toward an invariant Arg (651). A striking 5-LOX specific feature is Lys in place
of Leu at this position as part of a di- or tri- Lys peptide (Fig 13). While numerous salt links
anchor the C-terminal helix to the body of the protein in the structures of the two homologues
noted above, none of these salt links is conserved in the 5-LOX sequence. As a consequence of
the lysine-rich sequence and the absence of helix-anchoring salt-links, the orientation of the
terminal helix is less favorable and the C-terminal ligand to the active site Fe is likely to be
tenuously restrained. Conservative mutations in the carboxy terminal helix have been noted to
reduce enzyme expression levels and activity (Kuhn, Anton et al. 2003). These observations led
us to replace 5-LOX KKK653-655 with the corresponding sequence from 8R-LOX (ENL) in an effort
to stabilize the enzyme for crystallographic studies. The mutant human enzyme (herein referred
to as Stable-5-LOX) was prepared in the context of a soluble 5-LOX (Sol-5-LOX) which lacks
putative membrane insertion amino acids (Δ40-44GS, W13E, F14H, W75G, L76S) as well as a
pair of cysteines (C240A, C561A) predicted to be proximal in the 5-LOX structure. Substitution
of the membrane insertion loops was based on a similar approach with the Plexaura
homomalla enzyme, which shares both these amino acids and Ca2+-binding residues with 5-LOX
in the amino terminal membrane-binding domain (Neau, Gilbert et al. 2007). The substitution
of KKK with ENL in this context led to a ~3°C increase in the melting temperature of the
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Figure 12. Stabilization of human 5-LOX. (A) Superposition of the C-terminal regions of the
structures of 15-, 8R-, and Stable-5-LOX. The C-terminal segment that leads to the catalytic Fe
emanates from the helix that terminates at amino acid 655 (5-LOX numbering; Stable-5-LOX,
pink; 8R-LOX green; 15-LOX, blue). Highly conserved amino acids (Leu and Phe/Tyr) and an
invariant salt link (Asp-Arg) are depicted in stick rendering. (B) Detail of the turn at the end of
the terminal helix. The 5-LOX–specific Lys (replaced in Stable-5-LOX with Leu) is modeled at
position 655 as its most common rotamer (transparent sphere rendering). As positioned, it
would interfere with the invariant salt-link and cation-π interactions. All figures were generated
with Pymol (31). (C) Thermal denaturation of Stable-5-LOX (red) and the parent enzyme Sol-5LOX (blue). Fluorescence (F) is monitored as a function of temperature. Tm (with SD) 56.6°C
(±0.4°) and 59.7°C (±0.2°) for Sol-5-LOX and Stable-5-LOX, respectively. (D) High-performance
liquid chromatography chromatogram. Product analysis of Stable-5-LOX reveals both 5-HETE (5HPETE reduced by the addition of triphenylphosphine, TPP) and leukotriene A4 hydrolysis
products (5,12-diols).
enzyme (Fig 12c). Moreover, Stable-5-LOX has a longer activity half-life at 37 °C (~16 hrs vs. ~7
hrs, Fig 14). Furthermore, Stable-5-LOX produces both the intermediate 5S-HPETE and the
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product leukotriene A4 (Fig 12, Fig 15). In addition, we measure a Km for AA of ~8μM (Fig 16),
equivalent to that of the wild-type enzyme (Aharony and Stein 1986). These observations are
consistent with the proposal that the KKK sequence is destabilizing, and that its substitution
does not impact catalytic fidelity. The structure of Stable-5-LOX was determined to 2.4 Å
resolution (Figure 17a; Table 1).

Figure 13. Alignment of the C-terminal sequences of 5-LOX (blue) and non-5-LOX (black). The
Lys-rich peptide of the former is highlighted in red, the highly conserved Leu in teal. The
underlined sequence in H. sapiens 5-LOX was replaced by the underlined sequence in P.
homomalla 8R-LOX.
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Figure 14. Enzyme half-life of Sol-5-LOX and Stable-5-LOX. Enzyme activity (ΔA238) was
monitored over the course of 24 hrs at 37°C for Sol-5-LOX (red) and Stable-5-LOX (blue).

Figure 15. HPLC chromatogram of Sol-5-LOX products. Product analysis of Sol-5-LOX reveals
both 5-HETE (5-HPETE reduced by the addition of triphenylphosphine, TPP) and the
Leukotriene A4 hydrolysis products (5,12 diols).
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Figure 16. Kinetic analysis of Stable-5-LOX. The activity of Stable-5-LOX vs substrate
concentration. Non-linear regression analysis yields the hyperbolic curve. The KM of Stable-5LOX for arachidonic acid is 11.1 ± 2.1 μM.
The canonical LOX framework contains two distinct domains: the amino terminal “C2like” domain (~120 amino acids), which in 5-LOX confers Ca2+-dependent membrane binding
(Chen, Zhang et al. 1998; Chen and Funk 2001; Hammarberg, Reddy et al. 2002; Kulkarni, Das et
al. 2002), and the larger catalytic domain. The latter is primarily α-helical and harbors the nonheme catalytic iron. The iron is coordinated by three conserved histidines (His- 367, 372, 550)
as well as the main-chain carboxylate of the C-terminus (I673). Another structurally distinct
conserved feature in this domain, previously described in detail by Minor et al (Minor, Steczko
et al. 1996) for soybean LOX L-1, is an arched helix that shields access to the catalytic iron. At
the vertex of the 5-LOX arched helix is an invariant Leu 414 (Fig 17b) that in other lipoxygenases
has been proposed to control access of O2 to the substrate (Knapp, Seebeck et al. 2001; Knapp
and Klinman 2003) or position the substrate pentadiene for attack (Neau, Gilbert et al. 2009).
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Additional amino acids from the arched helix that help define the catalytic site are Asn-407,
Leu-420, Phe-421 and His-432. The crystal structure of 5-LOX reveals a striking variation on the

Figure 17. Structure of Stable-5-LOX. (A) A cartoon rendering of 5-LOX. The two views differ by
a 180° rotation about the vertical line. The N-terminal C2-like domain is in dark gray, and the
catalytic domain in light gray. The distinctive arched helix is in blue, and helix α2 in red. The
internal cavity, generated with CastP (32), is in pink, and the Fe is an orange sphere. The
positions of the mutated amino acids are indicated in mesh rendering: green, putative
membrane insertion residues; yellow, proximal cysteines; and blue, the KKK→ENL substitution.
(B) Detail of the relation of the arched helix and helix α2 to the active site as viewed from the
perspective indicated by the red arrow in (A). Shown in stick rendering are amino acids 406,
414, 420, and 421 of the arched helix and Phe177 and Tyr181 from helix α2 (with transparent
surface rendering). The latter two bulky amino acids obstruct access to the cavity. The
proximity of the C-terminal Ile673 to the corked portal is apparent.
classic lipoxygenase fold in helix α2 which defines one edge of the active site. In the structures
of 8R- and 15-LOX helix α2 is 6-7 turns, while in 5-LOX it is a short 3-turn helix flanked by
extended loops. The shortened helix is positioned at ~45° to its counterparts in the 8R- and 15enzymes (Fig 18a, b). The unique orientation of helix α2 in Stable-5-LOX greatly limits access to
the catalytic iron and yields a distinctive active site cavity. Specifically, the side chains of F177
and Y181 are positioned inward and close off an access channel to the catalytic iron that is
observed in both the 8R- and 15-LOX structures (Fig 19a). The remainder of the secondary
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Figure 18. The positioning of helix α2 is unique in 5-LOX. (A) A 5-LOX cartoon is rendered in
pink, 15-LOX in blue and 8R-LOX in green. Conserved aromatic amino acids (Phe169 and
Trp201) that flank the region are in stick rendering. Phe177 and Tyr181, which make up the
cork that helps define the active site, are in stick. The catalytic iron is an orange sphere. (B) A
full overlay of the three structures in which it is apparent that, with the exception of α2, the
secondary structural elements in the enzymes are conserved. The box indicates the region
amplified in (A).
structural elements, and their relative orientations, are maintained (Fig 18b). In addition, the
structural context of the Lys-rich peptide also appears conserved as the C-terminal helices
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superimpose. However, it is apparent that a Lys at position 655 would interfere with invariant
salt link and cation-π interactions (Fig 12b).
In 5-LOX the active site is an elongated cavity, with no clear access to bulk solvent, lined
with both invariant and 5-LOX specific amino acids. Leu- 373, 368, 414, 607 and Ile-406 are
conserved in all AA-metabolizing lipoxygenases (Neau, Gilbert et al. 2009) and form a
structurally similar constellation of branched hydrophobic side chains that envelop the region
where the pentadiene must be positioned for catalysis. Y181, A603, A606, H600 and T364 are
specific to 5-LOX sequences and the small side chains of A603 and A606 appear to be required
for the conformation of Y181 which, along with F177, “corks” the cavity at one end. Y181 is in
van der Waals contact with A603, and the small side chains of both 603 and 606 allow both
bulky aromatics (F177, Y181) to point into the cavity where they can be shielded from solvent.
An additional 5-LOX specific amino acid, W599, appears to buttress the FY cork from one side.
The closed cavity (volume = 663Å3) raises the question of how substrate gains access to the
catalytic iron. Two possibilities can be envisioned: (1) Removal of the FY cork at one end of the
cavity and/or movement of W599 that secures it, or (2) A rotamer shift of W147 at the opposite
end. A rotamer shift in W147 would require only rotation of the side chain, while the former
may require both side chain and main chain movements in two amino acids. This observation
suggests that AA may enter 5-LOX from the opposite direction as it does in the 15- or 8Renzymes, which lack the FY cork. This site of entry fits well with what is known about the
catalytic mechanism: H abstraction and peroxidation occur on opposite sides of the pentadiene
(Schneider, Pratt et al. 2007). The S-stereochemistry of the 5-LOX product is consistent with an
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Figure 19. The 5-LOX active site. Internal cavities calculated with CastP (32). (A) The active site
cavity of 15-LOX (2P0M) is in yellow. Invariant Leu and Ile side chains are in green stick
rendering. The 5-LOX FY cork is superposed on the 15-LOX cavity and plugs the entrance. (B)
The equivalent orientation of the active site cavity of Stable-5-LOX in pink; invariant Leu and Ile
side chains in green sticks. Note the similarity of the positions of these amino acids to their
counterparts in 15-LOX (A). Iron coordination sphere amino acids (C, white) are in stick
rendering, and the iron an orange sphere. (C) 5-LOX amino acids that contribute to the active
site cavity. Entry into this cavity requires a conformational change.
“inverse” orientation of AA relative to that for the 15- and 8R- enzymes (Walther, Ivanov et al.
2001; Coffa and Brash 2004). An opening at the W147 end would allow the AA to enter methyl
end first and position the substrate for the production of the S isomer of 5-HPETE. While the
above model is attractive, the structure does not rule out the alternative: that the AA enters
the same portal it does in 8R- and 15- enzymes, in which case carboxylate-first entry achieves
the same binding orientation and reaction specificity.
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Figure 20. Representative electron density of 5-LOX active site. The 2│Fo│-│Fc│ density in the
active site cavity contoured at 1.5 σ.

The 2.4 Å structure of 5-LOX reveals an active site which, despite a conserved
constellation of five invariant amino acids, is clearly distinct from the active sites of the
arachidonic acid metabolizing lipoxygenases for which structures are available. The structure
provides a context for the development of 5-LOX specific inhibitors and together with the
crystal structures of Five Lipoxygenase Activating Protein (Ferguson, McKeever et al. 2007) and
the downstream enzyme Leukotriene C4 Synthase (Ago, Kanaoka et al. 2007; Martinez Molina,
Wetterholm et al. 2007), a molecular model for early events in leukotriene biosynthesis.
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Table 1 Data Collection and refinement statistics of Stable-5-LOX
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Materials and Methods
Construction of Plasmid for Protein Expression
The 5-LOX insert in pCR2.1 was amplified by the polymerase chain reaction, cloned into
pET28b (Novagen), and then subcloned into pET14b for leaky expression. Mutations were
constructed using whole plasmid PCR (Neau, Gilbert et al. 2009). Where possible primers were
constructed to contain silent mutations that facilitated screening of plasmids. Small scale
expression to assess expression levels and solubility of the various mutant 5-LOXs was carried
out by autoinduction (Studier 2005).

Protein Expression and Purification
Rosetta 2 (DE3) cells (Novagen) harboring the pET14b-Stable-5-LOX or pET14b-Sol-5-LOX
plasmids were grown in Terrific Broth containing 34 µg ml-1 chloramphenicol and 100 µg ml-1
ampicillin at 37 °C for 3.5 h and then shifted to 20 °C for an additional 26 h. Cells were
harvested, pelleted, and frozen at -80 °C. Cells were resuspended in Bugbuster (Novagen,
2ml/g) supplemented with 1 µM Pepstatin, 100 µM PMSF, and DNaseI (2 Kunitz/g) (all Sigma).
The suspension was lysed in a French pressure cell and centrifuged at 40,000xg (30min).
Clarified lysate was applied to a HisTrap 5 ml Ni2+- Sepharose column (GE Healthcare)
equilibrated in 50 mM Tris (pH 8.0), 500 mM NaCl, 20 mM imidazole and eluted with a linear
gradient to 50 mM Tris pH 8.0, 500 mM NaCl, 200 mM imidazole on an AKTA FPLC (GE
Healthcare). The peak fractions were concentrated in an Amicon Ultra 30K (Millipore) to a final
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volume of 2 ml. The concentrated protein was applied to a HiLoad 16/60 Superdex 200 pg (GE
Healthcare), equilibrated in 20 mM Tris pH 8.0, 150 mM NaCl, 5 mM TCEP·HCl, and eluted as
both a dimer and monomer. All experiments were performed with monomeric enzyme; there
are no contacts in the crystal lattice consistent with a stable dimer. Protein purity was checked
by SDS-PAGE. Enzyme activity was monitored with a UV-spectrophotometer with diode array
detector (Agilent) and protein was frozen in liquid N 2.

Product Assays
Incubations were conducted in 0.5 ml 0.1 M Tris pH 7.5 containing 150 mM NaCl and 1
mM CaCl2 with 1-20 g/ml 5-LOX enzyme. The reaction was initiated by addition of arachidonic
acid (10 – 100 M) added in 1-5 l ethanol and monitored by UV spectroscopy until completion
of reaction (5-10 min). Products were extracted by adjusting the solution to ~pH 4 by addition
of 50 l 1 M KH2PO4 plus 5 l 1N HCl and vigorous mixing with two volumes of
dichloromethane. After a brief centrifugation to clear the phases, the lower organic layer was
collected, washed twice with 0.5 ml water, taken to dryness under a stream of nitrogen, and
then dissolved in a small volume of methanol for storage at -20C prior to HPLC. Reversedphase HPLC was carried out using Agilent 1100 series equipment with a Waters C18 Symmetry
column (25 x 0.46 cm), a solvent of acetonitrile/water/glacial acetic acid (60:40:0.01, v/v/v) or
methanol/water/glacial acetic acid (80:20:0.01, v/v/v), a flow rate of 1 ml/min, with UV
monitoring at 205 nm, 220 nm, 235 nm and 270 nm. The chirality of the product was confirmed
as 5S: Mobile phase hexane/methanol 100:2; 1ml/min; Chiralpak AD column (4.6x250mm).
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The HETEs were made into the methyl esters before chiral analysis using ethereal
diazomethane.

Enzyme Assays
Sol-5-LOX and Stable-5-LOX were assayed over the course of 24 hrs by monitoring the
absorbance at 238 nm in an Agilent 8453 Diode Array Spectrophotometer. Enzyme was
incubated at 37°C in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM TCEP. Assays were
performed in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM CaCl2. The reaction was initiated
by the addition of 65 μM AA and monitored at room temperature. Enzyme assays for K M
determination were performed in similar conditions, except that the concentration of AA varied
from 1.5 to 26 μM. The KM was calculated by non-linear regression analysis of a plot of velocity
vs. substrate concentration (Sigma Plot 9).

The data represent the results of duplicate

experiments.

Melting Curves
Melting temperature assays were performed according to the protocol described by
Ericsson et al.(Ericsson, Hallberg et al. 2006) Protein was diluted to 1 M in a final volume of
150 l 5X SYPRO® Orange protein stain (Invitrogen). Samples were aliquoted in triplicate
volumes of 40 l in a 96-well reaction plate. The plate was subjected to a linear thermal shift
from 5 to 94 C in one degree increments in a 7500 Fast Real-Time PCR System (Applied
Biosystems). The SYBR Green cutoff filter was used for fluorescence detection of denaturing
protein-SYPRO® Orange binding. The resulting data were exported to Sigma Plot 9, and the
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sigmoidal part of the curve was averaged for each triplicate. The averaged curves were
subsequently fit to a four parameter sigmoidal equation. The Tm values reported are the results
of four independent experiments, each in triplicate, with multiple protein preparations.

Crystallization
Stable-5-LOX monomer crystals were grown by hanging-drop vapor diffusion at 295 K by
mixing 1 µl protein (8 mg/ml) and 2 µl reservoir solution containing 8-10% Tacsimate pH 6.0
(Hampton Research). The crystals were soaked in 70% Tacsimate pH 6.0 and then frozen for
shipment and data collection. Crystals belong to space group P2 1 (a=54.99, b=202.67, c=76.47
Å, β=109.35°); there are two monomers in the asymmetric unit.

Structure Determination
Diffraction data were collected at 100 K at the NE-CAT beamline 24-ID-E at the
Advanced Photon Source, Argonne, Illinois. Data were processed with Xia2. A search model
based on the 8R-lipoxygenase structure (40% sequence identity) was prepared with Chainsaw.
Molecular replacement was performed with Phaser (Z-scores 31.47, 29.24). Initial refinement of
the Chainsaw model (which retains atoms common to 8R- and 5-LOX) as placed resulted in an
Rfree=0.39 in REFMAC, while that of the equivalent polyalanine model reached 0.45. Chainsaw,
Phaser and REFMAC are all part of the CCP4 suite (Collaborative Computational Project 1994).
Manual model building was performed with Coot (Emsley and Cowtan 2004). Refinement was
continued in Phenix (Zwart, Afonine et al. 2008) with non-crystallographic symmetry restraints,
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individual atomic displacement factors (B-factors), and automatic water picking. The final
model has Rwork and Rfree values of 18.0 and 21.0, respectively. Illustrations were prepared with
Pymol (DeLano 2002).
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CHAPTER THREE
A SINGLE AMINO ACID PROVIDES A SWITCH TO
CONVERT HUMAN 5-LIPOXYGENASE TO A 15LIPOXYGENASE
Overview
The initiation of synthesis of both the pro-inflammatory LTs and the anti-inflammatory
LXs requires 5-LOX activity. 5-LOX has been implicated in many disease states including asthma,
atherosclerosis, and cancer. 5-LOX is a notoriously unstable enzyme, and its lability is thought
to help limit the production of the LTs. I have recently focused my attention on Ser663 of 5-LOX,
which lies 10 amino acids removed from the C-terminal isoleucine. Ser663 has been shown to be
phosphorylated by extracellular signal-regulated kinase 2(ERK2) in vitro. I mutated Ser663 to Asp
for a homogenous preparation of a phospho-mimicking Stable-5-LOX. The crystal structure of
the Stable-5-LOX S663D was determined in the absence and presence of AA. The structure of
the control enzyme, Stable-5-LOX-S663A, was also solved in an apo form. The crystal structure
of the S663D enzyme with AA, combined with both altered substrate and product profiles for
the modified enzyme, lead me to suggest that phosphorylation of 5-LOX at Ser663 converts the
enzyme to a robust 15-LOX. These results suggest that the phosphorylation of 5-LOX at Ser663
could not only down-regulate LT production, but could also stimulate LX production in cells
which do not express 15-LOX. Thus 5-LOX, which synthesizes the pro-inflammatory LTs, can be
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converted to an enzyme that independent of 15-LOX could synthesize the anti-inflammatory
LXs.

Introduction
LTs and LXs, derived from AA, are potent mediators of the inflammatory response.
Upon leukocyte activation, AA is released from the nuclear membrane by the action of cPLA2
and binds FLAP. The increased Ca2+ concentration of the activated cells simultaneously
promotes translocation of 5-LOX to the nuclear membrane where it acquires its substrate from
FLAP. AA is converted to LTA4 in a two-step reaction with 5-HpETE as an intermediate. While 5LOX production of LTA4 promotes inflammation, 5-LOX is also required for the synthesis of the
LXs, which are structurally related compounds with anti-inflammatory properties that promote
the resolution of inflammation (Serhan, Hamberg et al. 1984). LXs are the products of
successive lipoxygenase reactions requiring both 15-LOX and 5-LOX activities. 15-LOX and 5-LOX
are generally not present in the same cell types, and thus LX synthesis is thought to be
transcellular (Edenius, Stenke et al. 1991).
LT production has been shown to be regulated by 5-LOX phosphorylation, and three
kinase targeted sites have been reported: Ser 271, 523 and 663 (Werz, Klemm et al. 2000;
Werz, Burkert et al. 2002; Werz, Szellas et al. 2002; Werz, Burkert et al. 2003). Serine 663 has
been shown to be a substrate for ERK2 in vitro. Furthermore, 5-LOX product formation has
been shown to be depressed in cells in which ERK2 activity is up-regulated (Pergola, Dodt et al.
2008). In order to understand the structural basis for altered LT production as a consequence
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of phosphorylation at Ser663, I prepared a 5-LOX mutant in which Ser663 was substituted to
Asp663. The mutation of a Ser to an Asp is a well-established method to approximate the
phosphorylated form of an enzyme for studies which require a homogenous sample of the
modified enzyme. For example, two phospho-mimicking aspartates were substituted in Mek-1
where phosphorylation is known to occur on specific serine residues. Mek-1 is an upstream
kinase that is responsible for phosphorylating mitogen-activated protein kinases (MAP kinases),
and when the phospho-mimetic Mek-1 was expressed, MAP kinases were constitutively
phosphorylated by Mek-1(Huang and Erikson 1994). Also, the conversion of a Ser to Asp at a
specific phosphorylated PKA-site in the microtubule-associated protein Tau causes a large
conformational change similar to phosphorylation of this specific serine residue. Furthermore,
similar to phosphorylated wild-type Tau, this phospho-mimetic Tau promotes microtubule
growth (Leger, Kempf et al. 1997). The ability to approximate the effects of phosphorylation by
introduction of a phospho-mimetic residue by site-directed mutagenesis is a powerful method
for obtaining homogenous protein that can be used for subsequent biochemical experiments.

Results and Discussion
Stable-5-LOX S663D was over-expressed, purified, and crystallized using similar
conditions to those previously reported for Stable-5-LOX (Gilbert, Bartlett et al. 2011). To
understand the consequence of the Asp substitution at Ser663, I first analyzed the rate of
product formation along with product specificity of the phospho-mimetic enzyme upon
addition of AA. To our surprise, Stable-5-LOX S663D converts AA to 15S-HpETE, (Fig 21) and it
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catalyzes this reaction at a more robust rate than the transformation of AA to 5-HpETE by
Stable-5-LOX (Fig 22). To test the extent of the altered catalytic activity of Stable-5-LOX S663D,

Figure 21. HPLC chromatogram of Stable-5-LOX S663D products. Stable-5-LOX S663D catalyzes
the transformation of AA to a mixture of hydroperoxide products. HPLC trace of Stable-5-LOX
S663D products reveals mostly 15-HETE with ~20% 5-HETE.

Figure 22. Relative rates of 5-LOX and phospho-mimetic 5-LOX. Stable-5-LOX S663D nearly
doubles HETE production as compared to the parent Stable-5-LOX as monitored in triplicate at
238 nm on UV-VIS spectrophotometer.
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we employed substrates with a different number of double bonds or with a more bulky head
group. We chose dihomo-γ-linolenic acid (DGLA) because it has twenty carbons like the
preferred substrate AA, but it lacks the double bond at C5, which is critical for formation of 5HpETE. Our Asp substituted Stable-5-LOX oxygenated DGLA at a rate similar to that for AA but
only after a lag period of ~50 seconds (Fig 23). In contrast, the progenitor Stable-5-LOX
oxygenated DGLA at a rate reduced ~100X compared to AA. The second alternative substrate
utilized was N-arachidonyl glycine (NAGly), which has a glycine substituted on the carboxylate

Figure 23. Kinetic characterization of 5-LOX and phospho-mimetic 5-LOX with various
substrates. The structures of AA, DGLA, and NAGly are colored at top purple, orange, and
green, respectively. The UV-VIS trace of Stable-5-LOX (circles) and Stable-5-LOX S663D
(triangles) are monitored over 30-90 seconds. The S663D substituted Stable-5-LOX transformed
both DGLA and NAGly into a hydroperoxide at a rate similar to that for AA after a lag period of
~50 seconds.
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of AA through an amide bond linkage. This larger head-group could interfere with substrate
acquisition if 5-LOX utilizes the carboxylate for recognition. Our parent enzyme Stable-5-LOX
was relatively slow at transforming NAGly compared to AA; however, the Asp substituted
Stable-5-LOX oxygenated NAGly at rate similar to that for AA but with ~50 second lag time (Fig
23). The catalytic lag period for oxygenation of the alternative substrates by Stable-5-LOX
S663D can be interpreted in multiple ways: a conformational movement of key α-helices
around the active site, rotamer switch of amino acids near each end of the active site cavity, or
a mixture of both movements could be required before oxygenation. The Asp substitution at
Ser663 in 5-LOX may make the enzyme less rigid and more accommodating to various substrates.
The product that Stable-5-LOX S663D makes upon addition of AA is the 15(S) isomer of
15-HpETE. If antarafacial oxygenation rules are followed by our 5-LOX S663D mutant, the AA
entry would have to be flipped in orientation relative to its positioning in the wild-type enzyme.
So if the wild-type 5-LOX binds AA with head first entry, the phospho-mimetic 5-LOX would
require tail first entry. If AA enters Stable-5-LOX S663D in the same orientation as the wild-type
enzyme with the carboxylate of AA positioned similarly except that C-13 of AA is poised for H
abstraction, then the oxygenation product on C15 would be in an R configuration yielding 15RHpETE. Both the DGLA and NAGly kinetic data support flipped substrate positioning of AA in the
S663D version of Stable-5-LOX as compared to the “unphosphorylated” 5-LOX. DGLA does not
have the key C7 pentadiene or the necessary double bond at C5 for 5S oxygenation, but the
double bond at C15 on DGLA would allow for oxygenation if DGLA entry is flipped. AA is a
symmetrical molecule in respect to number of atoms from the midpoint C10. Double bond
positions are symmetrical as they emanate from C10 at positions +1 and +4 from the midpoint.
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The ends of AA are also of similar length from the C10 center totaling +10 atoms away from the
midpoint with the carboxylate oxygen at the head and the ω-methyl carbon at the tail. The
introduced negative charge of the Asp663 could alter the carboxylate recognition motif for head
first entry of AA. Without the ability of the enzyme to neutralize the carboxylate of AA in the
hydrophobic catalytic pocket, tail first entry of AA could be favored. Tail first entry dictates that
the AA carboxylate is positioned at the Phe171/Tyr181 end of the U-shaped binding site and the
methyl tail at the Trp147 end. For head-group first entry, the positioning of AA is flipped in
orientation.
To further test carboxylate vs. tail entry of AA into 5-LOX and the 5-LOX Asp663, we
utilized the endocannnabinoid compound NAGly. The addition of a glycine to the carboxylate
of AA renders a more bulky head group that could alter how 5-LOX recognizes the substrate.
Stable-5-LOX could not oxygenate NAGly efficiently compared to AA; however, the Stable-5-LOX
S663D catalyzed the oxygenation quite readily after a lag period. The data support that the
phospho-mimetic 5-LOX could allow tail first entry of NAGly rendering the recognition of the
head-group superfluous. The addition of the large glycine head-group could preclude any
specific carboxylate recognition that wild-type 5-LOX utilized for substrate acquisition. Further
reverse phase HPLC analysis of NAGly oxygenation products by 5-LOX S663D would aid in the
identification of head vs. tail entry.
The increased rate of AA oxygenation by the 5-LOX S663D compared to the progenitor
5-LOX could be interpreted multiple ways. The wild-type 5-LOX, which catalyzes both the
oxidation of AA and dehydration of 5-HpETE to LTA4, has a two-step reaction; hence, two
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different substrates are competing for the same active site. Stable-5-LOX S663D only performs
the oxygenation reaction on AA and doesn’t have the 15-HETE product competing for the active
site. The phospho-mimetic 5-LOX may also bind the substrate with different affinity, and the
turnover rate may be faster not because of catalysis but due to differences in the rate of
substrate release. Further kinetic analysis will be required to help elucidate these details.
Another experiment that is relevant to LOX biology would be testing the ability of Stable-5-LOX

Figure 24. Superimposition of 5-LOX and phospho-mimetic 5-LOX structures. Stable-5-LOX
and Stable-5-LOX S663D are colored blue and green, respectively. The structures are
superimposed to show that virtually no change has occurred by the substitution of a Ser for an
Asp at position 663, which is ten amino acids removed from the C-terminal carboxylate that
binds the catalytic iron. The altered product specificity of Stable-5-LOX S663D cannot be
understood with just the apo structure.
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(+/- S663D) to oxygenate arachidonyl phospholipids and cholesteryl linoleate. Both of these
molecules are viable substrates of the LOX isozyme 15-LOX1 (Murray and Brash 1988; Kuhn,
Barnett et al. 1993; Belkner, Stender et al. 1998). If tail first entry is preferred in 5-LOX S663D,
then arachidonyl phospholipids and cholesteryl linoleate should be metabolized by the
phospho-mimic 5-LOX.
In order to understand the switch in regio-specific oxygenation of AA by Stable-5-LOX
S663D, we determined the crystal structure of Stable-5-LOX S663D in the presence and absence
of AA at 2.25 Å and 2.1 Å, respectively. The apo structure of the Asp substituted Stable-5-LOX
superimposes with high fidelity on the parent Stable-5-LOX except in the region of Asp663 and
Asp665 (Fig 24). The Asp663 is ten amino acid removed from the C-terminal carboxylate, which
provides a ligand for the catalytic-iron coordination sphere. The apo structure of Stable-5-LOX
S663D did not reveal the conformational switch required for altered product specificity;
moreover, the crystal structure of the control mutant Stable-5-LOX S663A also did not reveal
any conformational change in the C-terminal tail. However, the melting temperature of Stable5-LOX S663D is ~4.5 °C lower than the parent Stable-5-LOX (Fig 25). The structural basis of the
decreased stability is not aparent in the apo crystal structure of Stable-5-LOX S663D, but with
the addition of AA, the structure reveals large conformational flexibility (Fig 26). Both the
segmented α2 and the arched helix undergo extensive remodeling in the presence of substrate.
The remodeling, which includes the reorientation of helical segments and disordering of
extensive non-helical and helical regions, results in an exposed active site, in an open
conformation. The loop (residues 171-176) prior to the first segment of α2 is no longer visible in
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the electron density map, and the first segment of α2 is both shortened by three amino acids
and slightly shifted. The next segment of helix α2 (residues 190-194) and the following 3-turn
helix (residues 204-215) are fully displaced from their positions in the AA-free structure.
Moreover, an extensive portion of the “arched” helix is not visible: from Leu 414 at the apex of
the “arch” through to its C-terminal Gly428. Gly428 is the beginning of the four peptide repeat
GGGG with the first and last glycine of the repeat being conserved in all AA-metabolizing LOXs.
The result of the remodeling is a conspicuously accessible catalytic iron. Electron density

Figure 25. Thermal denaturation results of 5-LOX and phospo-mimetic 5-LOX. Proteins are
melted in a thermo-cycler in the presence of SYPRO® Orange (sigma), which has been shown to
bind to hydrophobic regions of a denaturing protein. The curve is fitted to a four parameter
sigmoidal equation for determination of TM. Stable 5-LOX has a TM of ~4.5 °C higher than the
Asp substituted Stable-5-LOX at Ser663.
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attributable to AA is visible in one of the monomers of the asymmetric unit. A U-shaped density
centered above the catalytic iron around C13 that can encompass ~16 carbons of the 20 carbon
substrate appears poised for attack (Fig 27). The density allows only ambiguous positioning of
the AA, as a forked density that represents a carboxylate is not visible on either end. Given that
the AA is not restrained at either end by protein-substrate contacts, this lack of density is not
surprising.

Figure 26. Structural comparison of phospho-mimetic 5-LOX structure plus and minus
arachidonic acid. The holo form of Stable-5-LOX S663D (grey) with AA (green sticks) and apo
form (arched helix, blue and α2, red) are superimposed. The proposed path that links
phosphorylation-mimic Ser 663 (Asp) with the active site is shown as sticks. Apo Stable-5-LOX
S663D residues are illustrated as purple sticks and holo form with AA as grey sticks. The
introduced negative charge on Ser663 could repulse Asp665 and cause a metastable domino
effect transduced by Trp605, whose side chain movement promotes repositioning of α2 to allow
differential access to the active site by AA.
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Figure 27. Electron density of arachidonic acid bound in Stable-5-LOX S663D. The structure of
Stable-5-LOX S663D soaked with AA. The 2Fo-Fc electron density map (blue) and Fo-Fc electron
density map (green, red) are contoured at 1σ and 3σ, respectively. The B-factor for the placed AA is
62.9.

Is the open conformation of the active site in Stable-5-LOX S663D plus AA a result of just
AA or a combination effect of AA plus the Asp663 substitution? In the structure of progenitor
Stable-5-LOX, the Ser663 is at the amino terminus of a 310 helix, and the side chain hydroxyl
participates in an H-bond with the side chain of Asp665. With the addition of the negative
charge to Ser663, Asp665 is nudged toward Arg666, which is in van der Waals contact with Phe610.
In the presence of AA, the loop that contains Phe610 is not visible and the helix that is just two
residues upstream, the penultimate helix of the catalytic domain, is slightly shifted so that
Trp605 bumps the first segment of the active-site defining helix α2. As a consequence, the α2-
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segment is shifted relative to the Stable-5-LOX and S663D structures in the absence of AA. In
addition, the arched helix is freed of the restraints that tether the C-terminal end by both
repositioning of helices and order-to-disorder transitions in the vicinity. In effect, a network of
H-bonds and van der Waals contacts is disrupted by the presence of the negative charge, and
this disruption could impact both α2 and the arched helix (Fig 26). Because it shelters the large
active site cavity, the arched helix has limited contact with the helical bundle that forms the
catalytic domain, and it is not adequately restrained to remain in position and enclose the
active site. The paucity of stabilizing contacts between the arched helix and the remainder of
the catalytic domain was dramatically illustrated by a structure of a truncated 12-LOX lacking
the C2-domain (3D3L); neither helix α2 nor the arched helix is positioned as it is in the full
length structures of 8R-LOX and 15-LOX. The fragile nature of the intra-molecular contacts
results in a 5-LOX poised for a striking conformational change by the introduction of a negative
charge distal to the active site, and as a result 5-LOX might switch the type of inflammatory
signals inside the cell. The biological consequence of phosphorylation of 5-LOX at Ser663 is still
to be determined in vivo, but the possibility of switching 5-LOX to a 15-LOX and increasing the
production of LXs could shift the paradigm of how inflammation is resolved.
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Table 2 Data Collection and refinement statistics

a
b

Values in parentheses are for the highest resolution shell.
〈 〉| ∑ ∑ 〈 〉
Rp.i.m. ∑ (
)∑ |

c

R = ∑║Fo│-│Fc║/ ∑ |Fo│, where Fo and Fc are the observed and calculated structure factor
amplitudes, respectively. Rfree was calculated using 3.2% of the total reflections.
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Materials and Methods
Construction of Plasmid for Protein Expression
The 5-LOX insert in pCR2.1 was amplified by the polymerase chain reaction, cloned into
pET28b (Novagen), and then subcloned into pET14b for leaky expression. The S663A and
S663D mutations were constructed using whole plasmid PCR (Neau, Gilbert et al. 2009). Small
scale expression to assess expression levels and solubility of the various mutant 5-LOXs was
carried out by autoinduction (Studier 2005).

Protein Expression and Purification
Rosetta 2 (DE3) cells (Novagen) harboring the pET14b-Stable-5-LOX S663D or pET14bStable-5-LOX S663A plasmids were grown in LB overnights. 5 ml of overnight was used for
inoculation into Terrific Broth containing 34 µg ml-1 chloramphenicol and 100 µg ml-1 ampicillin
at 37 °C for 3.5 h and then shifted to 20 °C for an additional 26 h. Cells were harvested,
pelleted, and frozen at -80 °C. Cells were resuspended in Bugbuster (Novagen, 2ml/g)
supplemented with 1 µM Pepstatin, 100 µM PMSF, and DNaseI (2 Kunitz/g) (all Sigma). The
suspension was lysed in a French pressure cell and centrifuged at 40,000xg (30min). Clarified
lysate was applied to a HisTrap 5 ml Ni2+- Sepharose column (GE Healthcare) equilibrated in 50
mM Tris (pH 8.0), 500 mM NaCl, 20 mM imidazole and eluted with a linear gradient to 50 mM
Tris pH 8.0, 500 mM NaCl, 200 mM imidazole on an AKTA FPLC (GE Healthcare). The peak
fractions were concentrated in an Amicon Ultra 30K (Millipore) to a final volume of 2 ml. The
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concentrated protein was applied to a HiLoad 16/60 Superdex 200 pg (GE Healthcare),
equilibrated in 20 mM Tris pH 8.0, 150 mM NaCl, 5 mM TCEP·HCl, and eluted as both a dimer
and monomer. All experiments were performed with monomeric enzyme; there are no
contacts in the crystal lattice consistent with a stable dimer. Protein purity was checked by SDSPAGE. Enzyme activity was monitored with a UV-spectrophotometer with a diode array
detector (Agilent) and protein was frozen in liquid N 2.

Product Assays
Incubations were conducted in 0.5 ml 0.1 M Tris pH 7.5 containing 150 mM NaCl and 1
mM CaCl2 with 1-20 g/ml 5-LOX enzyme. The reaction was initiated by addition of arachidonic
acid (10 – 100 M) added in 1-5 l ethanol and monitored by UV spectroscopy until completion
of reaction (5-10 min). Products were extracted by adjusting the solution to ~pH 4 by addition
of 50 l 1 M KH2PO4 plus 5 l 1N HCl and vigorous mixing with two volumes of
dichloromethane. After a brief centrifugation to clear the phases, the lower organic layer was
collected, washed twice with 0.5 ml water, taken to dryness under a stream of nitrogen, and
then dissolved in a small volume of methanol for storage at -20C prior to HPLC. Reversedphase HPLC was carried out using Agilent 1100 series equipment with a Waters C18 Symmetry
column (25 x 0.46 cm) or analyzed using a P680 HPLC system (Dionex, Sunnyvale, CA USA) with a
Discovery HS C18 column, a solvent of acetonitrile/water/glacial acetic acid (60:40:0.01, v/v/v) or

methanol/water/glacial acetic acid (80:20:0.01, v/v/v) or gradient of acetonitrile and water with
0.01 formic acid, a flow rate of 1 ml/min, with UV monitoring at 205 nm, 220 nm, 235 nm and
270 nm or with Dionex diode detector. The chirality of the product was confirmed as 5S or 15S:
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Mobile phase hexane/methanol 100:2; 1ml/min; Chiralpak AD column (4.6x250mm). The
HETEs were made into the methyl esters before chiral analysis using ethereal diazomethane.

Enzyme Assays
Stable-5-LOX S663D and the progenitor Stable-5-LOX were assayed by monitoring the
increase in absorbance at 238 nm in an Agilent 8453 Diode Array Spectrophotometer. The
different substrates AA, DGLA, and NAGly were diluted to 10 mM in 100% ethanol. Assays were
performed in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM CaCl2 with 1 µM protein. The
reaction was initiated by the addition of 65 μM of the respective substrate and monitored at
room temperature for 30-90 seconds. For measurement of relative catalytic rates of Stable-5LOX and Stable-5-LOX S663D, the protein was diluted to 1 µM in standard assay buffer, and
then the rate was monitored upon addition of 65 µM AA. The data represent the results of
triplicate experiments.

Melting Curves
Melting temperature assays were performed according to the protocol described by
Ericsson et al.(Ericsson, Hallberg et al. 2006) Protein was diluted to 1 M in a final volume of
150 l 5X SYPRO® Orange protein stain (Invitrogen). Samples were aliquoted in triplicate
volumes of 40 l in a 96-well reaction plate. The plate was subjected to a linear thermal shift
from 5 to 94 C in one degree increments in a 7500 Fast Real-Time PCR System (Applied
Biosystems). The SYBR Green cutoff filter was used for fluorescence detection of denaturing
protein-SYPRO® Orange binding. The resulting data were exported to Sigma Plot 9, and the
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sigmoidal part of the curve was averaged for each triplicate. The averaged curves were
subsequently fit to a four parameter sigmoidal equation. The Tm values reported are the results
of four independent experiments, each in triplicate, with multiple protein preparations.

Crystallization
Stable-5-LOX S663D or Stable-5-LOX S663A monomer crystals were grown by hangingdrop vapor diffusion at 295 K by mixing 1 µl protein (8 mg/ml) and 2 µl reservoir solution
containing 8-10% Tacsimate pH 6.0 (Hampton Research). Some crystals were grown in an
anaerobic chamber (Coy Laboratories®), and then soaked in 70% Tacsimate pH 6.0 with 1 mg/ml
AA for 3 hours. Crystals were then frozen in liquid nitrogen, if applicable inside an anaerobic
chamber for shipment and data collection. All crystals belong to space group P21; there are two
monomers in the asymmetric unit.

Structure Determination
Diffraction data were collected at 100 K at the NE-CAT beamline 24-ID-E at the
Advanced Photon Source, Argonne, Illinois. Data were processed with Xia2. The previously
solved Stable-5-LOX monomer was used for molecular replacement with Phaser (McCoy,
Grosse-Kunstleve et al. 2007). Manual model building was performed with Coot (Emsley and
Cowtan 2004). Refinement was performed in Phenix (Zwart, Afonine et al. 2008) with noncrystallographic symmetry restraints when applicable, individual atomic displacement factors
(B-factors), and automatic water picking. Illustrations were prepared with Pymol (DeLano
2002).
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CHAPTER FOUR
CONCLUSIONS
The production of the pro-inflammatory LTs and the anti-inflammatory LXs requires the
action of 5-LOX in the presence of liberated AA. The calcium activation and the translocation of
5-LOX to the nuclear membrane have been well documented, but the mechanistic details of 5LOX specific catalysis and the amino acids required for substrate positioning by this isozyme are
less understood. The auto-inactivation of 5-LOX, either through turnover or non-turnover based
mechanisms, have been noted; therefore, we focused our efforts on making a soluble and
stable form of 5-LOX that is more amenable to biochemical characterization and structure
solution. Our engineered form of 5-LOX designated Stable-5-LOX has membrane insertion loops
removed, oxidation sensitive cysteines near the active site mutated, and most importantly a
destabilizing tail sequence of the tripeptide KKK653-655 replaced to the 8R-LOX specific ENL at the
equivalent position. Thermal denaturation studies quantitated stabilization effects by the
replacement of this tri-lysine peptide. We enzymatically characterized the Km of Stable-5-LOX
for its natural substrate AA, and the kinetic binding constant is similar to the wild-type enzyme.
We analyzed the oxygenation products of Stable-5-LOX on AA by reverse phase HPLC. We also
quantitated the enzymatic half-life of 5-LOX mutants at 37 °C. These data all indicate that
Stable-5-LOX is a more soluble and stable form of 5-LOX, and because of these biophysical
features, we were able to determine a high resolution x-ray crystal structure of this enzyme.
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The structure of Stable-5-LOX has a similar fold to the other LOX structures with an Nterminal β-barrel domain and mainly α-helical C-terminal domain, which harbors the catalytic
iron. The most unique structural feature of 5-LOX as compared to the other solved LOX
structures is helix α2 of 5-LOX. In the 15-LOX and 8R-LOX structures, α2 is a long straight helix,
but in the Stable-5-LOX structure, α2 is a broken and shortened helix that zig-zags across the
axis of the normally long α2 helix. 5-LOX has two bulky aromatic residues, Phe177 and Tyr181 that
lie on helix α2. These two amino acids are positioned near the catalytic iron and cork one end of
the active site. If this “FY cork” is superimposed on the 15-LOX structure, these two amino acids
would block the possible entry site of AA into the active site of 15-LOX. All AA-metabolizing
LOXs have conserved leucine amino acids that line the catalytic pocket and are thought to help
position one of the three pentadienes of AA for oxygenation; however, the more peripheral
amino acids, such as Phe 177 and Tyr 181, help define the unique pocket for each LOX isozyme
and could help control the regio- and stereo-specific oxygenation for 5-LOX.
My second research focus was determining the consequence of phosphorylation of a
key Ser that has been shown to be phosphorylated in vitro by ERK2. Ser663 lies 10 amino acids
upstream from the C-terminal carboxylate and 8 amino acids downstream of Lys655 that has
been shown to modulate activity. Replacement of a Ser with a negatively charged amino acid
such as Asp or Glu has been shown to mimic a phosphorylated form of an enzyme. The
substitution of S663D in Stable-5-LOX and also wild-type 5-LOX resulted in a switch of
oxygenation specificity in that the normal 5-HETE product was diminished and a more prevalent
15-HETE product was observed. To further test this switch of oxygenation specificity, we
employed alternate substrates that either had a key double bond missing or a modified
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carboxylate head group. The products of 5-LOX S663D analyzed by RP-HPLC and chiral
chromatography along with alternative substrate data suggest that wild-type 5-LOX and 5-LOX
S663D not only oxygenate AA on different carbons, but AA orientation must be switched
between the enzymes. When both 5-LOX and 5-LOX S663D were co-incubated with AA, not only
was 15-HETE and 5-HETE detected by RP-HPLC but LXA4 and LXB4 were identified (Fig 28). The
implications that LX synthesis could be performed by only 5-LOX after ERK2 activation could
alter our understanding of the resolution of inflammation.

Figure 28. HPLC chromatogram of lipoxins. Reverse phase HPLC of products of Stable 5-LOX
and the phospho-mimetic Stable 5-LOX S663D co-incubated with AA. Each peak on the right
represents a different LX hydrolysis product with LXB4 and LXA4 eluting at 22.25 and 23.85
minutes, respectively. The LXB4 and LXA4 peaks are represented left with full diode readouts for
each peak.
The co-crystal structure of Stable-5-LOX S663D plus AA reveals striking conformational
flexibility of the LOX active site. To further test the specifics of 5-LOX specific oxygenation,
solving the crystal structure of Stable-5-LOX plus AA might illuminate the differences in AA
binding between the 5-HETE and 15-HETE catalysis of the two enzymes. All experiments have
been done in vitro in the absence of FLAP. FLAP is known to be necessary for in vivo production

77

of 5-HpETE and LTA4. Does Stable-5-LOX bind FLAP? Does Stable-5-LOX S663D still make
predominantly 15-HETE in the presence of FLAP? Does Erk2 alter product specificity of 5-LOX in
vivo? If so, does this suggest that modulators of 5-LOX activity that switch 5-LOX to 15-LOX can
be identified? Inhibition of 5-LOX to lower the amount of LTs is beneficial, but the resolution of
inflammation by hijacking the enzyme to produce LXs is potentially a more powerful approach
for the treatment of LT related diseases. The structure of human-5-LOX has opened multiple
avenues for new LT research, and the insights afforded from the phospho-mimetic 5-LOX S663D
could result in a paradigm shift in the development of therapeutics for the treatment of asthma
and other inflammatory diseases.
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